Inhibitory peptides for the diagnosis and / or treatment of tauopathies
Inhibitory hexapeptides target tau protein aggregation to treat Alzheimer's disease and other tauopathies, offering a dual diagnostic and therapeutic solution.
Patent Information
- Application Number
- JP2024532726
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-30
- Filing Date
- 2022-11-30
- Publication Date
- 2024-11-15
AI Technical Summary
Current treatments for Alzheimer's disease and other tauopathies are inadequate, with no effective disease-modifying therapies available, and there is a significant need for accurate antemortem diagnosis.
Development of inhibitory peptides, specifically hexapeptides and their derivatives, that can inhibit the pathological tau protein self-association process, particularly the PHF6-dependent assembly of tau into paired helical fibrils, enabling both therapeutic and diagnostic applications.
The hexapeptides effectively inhibit tau aggregation in vitro and can be used as therapeutics for tauopathies while also serving as probes for early diagnosis, providing a dual diagnostic/therapeutic approach.
Smart Images

Figure 2024542733000005 
Figure 2024542733000006 
Figure 2024542733000007
Abstract
Description
[Technical field]
[0001] Related Applications This application claims priority to European Patent Application No. 21 211 241, filed November 30, 2021, which is incorporated herein by reference in its entirety. [Background technology]
[0002] 2. Background of the Invention Alzheimer's disease is the most common cause of dementia and is clinically characterized by a loss of cognitive and behavioral abilities that interferes with an individual's daily life and activities. Alzheimer's disease will affect 14 million Europeans by 2030, with treatment costs of approximately 140 billion euros / year. Today, an estimated 6.2 million Americans aged 65 years and older are living with Alzheimer's disease, and this number is expected to increase to approximately 14 million by 2060 (Alzheimer & Dementia, 2021 Alzheimer's Disease Facts and Figures, 2021, Vol. 17(3): pp. 327-496). The disease is associated with the accumulation of abnormal proteins in the brain: beta-amyloid (Aβ) protein and tau protein. This accumulation leads to the formation of two distinctive brain lesions: (i) amyloid plaques, which are due to the extracellular (i.e., outside neurons) accumulation of Aβ protein, and (ii) neurofibrillary tangles, namely straight filaments (SFs) and paired helical filaments (PHFs), which are formed by the intracellular (i.e., inside neurons) accumulation of chemically modified (abnormally phosphorylated) tau protein. NFTs are not exclusive to Alzheimer's disease, but are characteristic lesions found in other conditions collectively referred to as tauopathies, including progressive supranuclear palsy (PSP), Pick's disease, and several others (Hutton et al., Nature, 1998, 393:702-705; Iseki et al., Acta Neuropathol., 2003, 105:265-270; Querfurth et al., N. Engl. J. Med., 2010, 362:329-344; Irwin et al., Parkinsonism Relat. Disord., 2016, 22:S29-S33; Silva et al., 8. Silva et al., eLife, 2019, 8:e45457).Despite extensive research aimed at finding approaches to halt the progression of Alzheimer's disease and related disorders, to date there are no effective therapies that can halt or reverse disease progression and cognitive decline (Graham et al., Annu. Rev. Med. 2107, 68:413-430; Medina et al., Int. J. Mol. Sci. 2018, 19:1160).
[0003] Tau is now considered to be an important target in the treatment of Alzheimer's disease and other tauopathies (Congdon et al., Nature Rev. Neurol., 2018, 14:399-415; Jadhav et al., Acta Neuropathol. Commun., 2019, 7:22; VandeVrede et al., Neurosci. Lett., 2020, 731:124-919). Indeed, previous studies focusing on the correlation between neuropathological changes (Aβ plaques and NFTs) and cognitive impairment in Alzheimer's disease have shown that the severity of cognitive impairment correlates best with the burden of abnormal tau (Nelson et al., J. Neuropathol. Exp. Neurol., 2012, 71:362-381). Tau is a stabilized microtubule-associated protein found primarily in the axonal compartment of neurons. In the adult human brain, six tau isoforms (352-441 amino acid residues, 37-46 kDa) are generated by alternative splicing from the MAPT gene on chromosome 17. These are distinguished by the absence or presence of one or two N-terminal inserts and the presence of three (3R) or four (4R) microtubule-binding repeats in the C-terminal half of tau. In addition to alternative splicing, tau can undergo several post-translational modifications, such as phosphorylation, acetylation, methylation, glycosylation, isomerization, O-GlcNAcylation, nitration, sumoylation, glycosylation, ubiquitination, and truncation, generating a large heterogeneity of tau molecules. Some of these post-translational modifications affect the localization and propensity of tau aggregates. Previous studies have shown that two six-residue segments of the tau sequence, 275 VQIINK 280(located at the beginning of repeat 2 - SEQ ID NO:1) and 306 VQIVYK 311 (located at the beginning of repeat 3 - SEQ ID NO:2) has been shown to drive tau aggregation. In particular, the assembly of tau protein into paired helical filaments (PHFs), also called PHF6. 306 VQIVYK 311 This motif coincides with the highest β-amyloid structural probability in tau. Point mutations in the hexapeptide region can decrease or increase aggregation depending on the altered β-amyloidogenic propensity (Barghom et al., Biochem., 2004, 43:1694-1703; von Bergen et al., J. Biol. Chem., 2001, 276:48165-48174).
[0004] Various tau-targeted therapeutic strategies have been explored, such as microtubule stabilization, immunotherapy, O-GlcNAc inhibition, inhibition of kinases, reduction of tau expression, and inhibition of tau aggregation (for reviews on various tau-based strategies, see, e.g., Gong et al., Drugs Aging, 2010, 27(5):351-365; Branden et al., Exp. Neurol., 2010, 223(2):304-310; Boutajangout et al., Gerontology, 2014, 60(5):381-385; Bakota et al., Drugs, 2016, 76(3):301-313; Congdon et al., Nat. Rev. Neurol., 2018, 14(7):399-415; Chong et al., Cell. Mol. Neurobiol., 2018, 38(5):965-980; Hoskin et al., Expert Opin. Investig. Drugs, 2019, 28(6):545-554; Dominguez-Meijide et al., Brain Sci., 2020, 10(11):858). Among these, inhibition of tau aggregation is the most widely studied strategy in Alzheimer's disease (Jouanne et al., Eur. J. Med. Chem., 2017, 139:153-167). Two different pharmacological strategies aimed at inhibiting tau aggregation have been developed. One strategy is to directly bind tau and maintain a conformation in which interactions are not possible, thus preventing aggregation (Cisek et al., Curr. Alzheimer's Res., 2014, 11:918-927; Seidler et al., Nature Chem., 2018, 10:170-176). The other strategy is based on interactions that promote the stabilization of non-toxic species (Cisek et al., Curr. Alzheimer's Res., 2014, 11:918-927; Seidler et al., Nature Chem., 2018, 10:170-176; Uversky et al., Biochim. Biophys. Acta (BBA) Proteins Proteom., 2013, 1834:932-951; Martinelli et al., Int. J. Mol. Sci., 2019, vol. 20:1322). [Prior art documents] [Patent documents]
[0005] [Patent Document 1] International Publication No. 2018 / 005867 Brochure [Non-patent literature]
[0006] [Non-Patent Document 1] Alzheimer & Dementia, 2021 Alzheimer's Disease Facts and Figures, 2021, Vol. 17(3): 327-496 [Non-Patent Document 2] Hutton et al., Nature, 1998, 393:702-705 [Non-Patent Document 3] Iseki et al., Acta Neuropathol., 2003, 105:265-270. [Non-Patent Document 4] Querfurth et al., N. Engl. J. Med. 2010, 362:329-344 [Non-Patent Document 5] Irwin et al., Parkinsonism Relat. Disord., 2016, vol. 22:S29-S33. [Non-Patent Document 6] Silva et al., 8. Silva et al., eLife, 2019, 8:e45457 [Non-Patent Document 7] Graham et al., Annu. Rev. Med. 2107, 68:413-430 [Non-Patent Document 8] Medina et al., Int. J. Mol. Sci., 2018, 19:1160 [Non-Patent Document 9] Congdon et al., Nature Rev. Neurol., 2018, 14:399-415 [Non-Patent Document 10] Jadhav et al., Acta Neuropathol. Commun., 2019, 7:22 [Non-Patent Document 11] VandeVrede et al., Neurosci. Lett., 2020, 731:124919 [Non-Patent Document 12] Nelson et al., J. Neuropathol. Exp. Neurol., 2012, 71:362-381. [Non-Patent Document 13] Barghom et al., Biochem., 2004, 43:1694-1703. [Non-Patent Document 14] von Bergen et al., J. Biol. Chem., 2001, 276:48165-48174. [Non-Patent Document 15] Gong et al., Drugs Aging, 2010, vol. 27(5): 351-365. [Non-Patent Document 16] Brunden et al., Exp. Neurol., 2010, 223(2):304-310 [Non-Patent Document 17] Boutajangout et al., Gerontology, 2014, 60(5):381-385 [Non-Patent Document 18] Bakota et al., Drugs, 2016, 76(3):301-313 [Non-Patent Document 19] Congdon et al., Nat. Rev. Neurol., 2018, 14(7):399-415 [Non-Patent Document 20] Chong et al., Cell. Mol. Neurobiol., 2018, 38(5):965-980 [Non-Patent Document 21] Hoskin et al., Expert Opin. Investig. Drugs, 2019, 28(6):545-554 [Non-Patent Document 22] Dominguez-Meijide et al., Brain Sci., 2020, Vol. 10(11): 858 [Non-Patent Document 23] Jouanne et al., Eur. J. Med. Chem., 2017, 139:153-167 [Non-Patent Document 24] Cisek et al., Curr. Alzheimer's Res., 2014, 11:918-927 [Non-Patent Document 25] Seidler et al., Nature Chem., 2018, 10:170-176 [Non-Patent Document 26] Uversky et al., Biochim. Biophys. Acta (BBA) Proteins Proteom., 2013, 1834:932-951. [Non-Patent Document 27] Martinelli et al., Int. J. Mol. Sci., 2019, 20:1322 [Non-Patent Document 28] Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York, 1983. [Non-Patent Document 29] "Remington's Pharmaceutical Sciences", E. W. Martin, 18th ed., 1990, Mack Publishing Co.: Easton, PA. [Non-Patent Document 30] Kalra et al., “10. Nanoparticles in Medical Imaging,” Nanoparticles in Analytical and Medical Devices, 2021, pp. 175–210. [Non-Patent Document 31] Jarzyna et al., Rev. Nanomed. Nanobiotechnol., 2010, vol. 2(2): 138-150. [Non-Patent Document 32] Huang, Dalton Trans., 2011, Vol. 40 (No. 23): 6087-6103
Non-patent document 33
Non-patent document 34
Non-patent document 35
Non-patent document 36
Non-patent document 37
Non-patent document 38
Non-patent document 39
Non-patent document 40
Non-patent document 41
Non-patent document 42
[0007] Although promising new therapeutic approaches targeting pathological forms of tau are being developed and tested in clinical trials, no disease-modifying treatments are yet available for Alzheimer's disease or other tauopathies. Furthermore, a major unmet need for the development and implementation of tau-targeted therapies is accurate antemortem diagnosis. [Means for solving the problem]
[0008] SUMMARY OF THE PRESENT APPLICATION The present inventors have identified a weakly non-amyloidogenic and weakly non-aggregating hexapeptide capable of efficiently inhibiting the pathological tau protein self-association process, in particular the PHF6-dependent assembly of tau into paired helical fibrils (PHFs). More specifically, the identified hexapeptide is a hexapeptide that is identical to the PHF6 peptide (VQIVYK, SEQ ID NO: 2) observed in Alzheimer's disease, as well as to itself and 374 HKLTF 378 (SEQ ID NO: 3), and the PHF6 peptide observed in Pick's disease. 336 QVEVKS 341 (SEQ ID NO: 4), which is responsible for the nucleation process of amyloid aggregates. In particular, the inventors have shown that the identified hexapeptides are capable of efficiently inhibiting PHF6 self-association in vitro and interacting in silico with both free tau protein and tau amyloid structures. The identified hexapeptides can be used as scaffolds for the development of new molecules that allow a dual diagnostic / therapeutic approach (theragnostics) for managing tauopathies. Indeed, starting from these hexapeptides, it is possible to generate molecules that can be used with a single tool (i) as therapeutic agents for treating Alzheimer's disease and other tauopathies and (ii) as probes for the early diagnosis of tauopathies.
[0009] Accordingly, the present invention relates to an inhibitory peptide for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject, the inhibitory peptide consisting of or comprising a hexapeptide or a derivative thereof, - The hexapeptides are SEQ ID NO:5 (3p), SEQ ID NO:6 (4p), SEQ ID NO:18 (4p inv ), SEQ ID NO: 7 (5p), SEQ ID NO: 19 (5p inv ), SEQ ID NO:8 (6p), SEQ ID NO:9 (8p), SEQ ID NO:21 (8p inv ), SEQ ID NO: 10 (9p), SEQ ID NO: 22 (9p inv ), SEQ ID NO: 11 (13p), SEQ ID NO: 23 (13p inv), SEQ ID NO: 12 (14p), SEQ ID NO: 24 (14p inv ), SEQ ID NO: 13 (23p), SEQ ID NO: 25 (23p inv ), SEQ ID NO: 14 (1tp), SEQ ID NO: 26 (1tp inv ), SEQ ID NO: 15 (4tp), SEQ ID NO: 27 (4tp inv ), SEQ ID NO: 16 (6tp), SEQ ID NO: 28 (6tp inv ), SEQ ID NO:55(0tp inv ), and SEQ ID NO: 56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - the hexapeptide derivative consists of an amino acid sequence selected from the above group, the amino acid sequence comprising a single conservative amino acid substitution or the amino acid sequence comprising conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6, Inhibitory peptides are provided.
[0010] In certain embodiments, an inhibitory peptide for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject consists of or comprises a hexapeptide or a derivative thereof: - Hexapeptides are SEQ ID NO:5 (3p), SEQ ID NO:6 (4p), SEQ ID NO:7 (5p), SEQ ID NO:8 (6p), SEQ ID NO:9 (8p), SEQ ID NO:10 (9p), SEQ ID NO:11 (13p), SEQ ID NO:12 (14p), SEQ ID NO:13 (23p), SEQ ID NO:14 (1tp), SEQ ID NO:15 (4tp), SEQ ID NO:16 (6tp), SEQ ID NO:26 (1tp inv ), SEQ ID NO:55(0tp inv ), and SEQ ID NO: 56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - a hexapeptide derivative consists of an amino acid sequence selected from the above group, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6.
[0011] In another embodiment, an inhibitory peptide for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject consists of or comprises a hexapeptide or a derivative thereof: - the hexapeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:6 (4p), SEQ ID NO:7 (5p), SEQ ID NO:9 (8p), SEQ ID NO:10 (9p), SEQ ID NO:11 (13p), SEQ ID NO:12 (14p), SEQ ID NO:13 (23p), SEQ ID NO:14 (1tp), SEQ ID NO:15 (4tp) and SEQ ID NO:16 (6tp); - a hexapeptide derivative consists of an amino acid sequence selected from the above group, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6.
[0012] In yet another embodiment, an inhibitory peptide for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject consists of or comprises a hexapeptide or a derivative thereof: - The hexapeptides are SEQ ID NO:5 (3p), SEQ ID NO:6 (4p), SEQ ID NO:18 (4p inv ), SEQ ID NO: 7 (5p), SEQ ID NO: 19 (5p inv ), SEQ ID NO:8 (6p), SEQ ID NO:9 (8p), SEQ ID NO:21 (8p inv ), SEQ ID NO: 10 (9p), SEQ ID NO: 11 (13p), SEQ ID NO: 12 (14p), SEQ ID NO: 24 (14p inv ), SEQ ID NO: 25 (23p inv ), SEQ ID NO: 14 (1tp), SEQ ID NO: 26 (1tp inv ), SEQ ID NO: 15 (4tp), SEQ ID NO: 27 (4tp inv ), SEQ ID NO: 28 (6tp inv ), SEQ ID NO:55(0tp inv ), and SEQ ID NO: 56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - a hexapeptide derivative consists of an amino acid sequence selected from the above group, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6.
[0013] In certain embodiments, an inhibitory peptide for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject consists of or comprises a hexapeptide or a derivative thereof: - The hexapeptides are SEQ ID NO: 6 (4p), SEQ ID NO: 18 (4p inv ), SEQ ID NO: 7 (5p), SEQ ID NO: 19 (5p inv ), SEQ ID NO: 14 (1tp), SEQ ID NO: 26 (1tp inv ), SEQ ID NO: 15 (4tp), SEQ ID NO: 27 (4tp inv ), SEQ ID NO: 16 (6tp), SEQ ID NO: 28 (6tp inv ), SEQ ID NO:55 (0tpinv), and SEQ ID NO:56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - a hexapeptide derivative consists of an amino acid sequence selected from the above group, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6.
[0014] In certain embodiments, an inhibitory peptide for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject consists of or comprises a hexapeptide or a derivative thereof: - the hexapeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:6 (4p), SEQ ID NO:7 (5p), SEQ ID NO:14 (1tp), SEQ ID NO:15 (4tp) and SEQ ID NO:16 (6tp), - a hexapeptide derivative consists of an amino acid sequence selected from the above group, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6.
[0015] In certain embodiments, an inhibitory peptide for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject consists of or comprises a hexapeptide or a derivative thereof: - Hexapeptides are SEQ ID NO: 14 (1tp), SEQ ID NO: 15 (4tp), SEQ ID NO: 16 (6tp), SEQ ID NO: 26 (1tp inv ), SEQ ID NO:55(0tp inv ), and SEQ ID NO: 56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - a hexapeptide derivative consists of an amino acid sequence selected from the above group, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6.
[0016] In certain embodiments, an inhibitory peptide for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject consists of or comprises a hexapeptide or a derivative thereof: - the hexapeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 14 (1tp) and SEQ ID NO: 16 (6tp), - a hexapeptide derivative consists of an amino acid sequence selected from the above group, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6.
[0017] In certain embodiments, the hexapeptide or hexapeptide derivative in the inhibitory peptide is linked to a heterologous moiety selected from the group consisting of a detectable moiety, a cell penetrating agent, a stability enhancing moiety, a tag that enables cellular degradation, and a blood-brain barrier shuttle moiety.
[0018] In other embodiments, the hexapeptide or hexapeptide derivative within the inhibitory peptide is linked to a detectable moiety and to a heterologous moiety selected from the group consisting of a cell permeation agent, a tag that enables cellular degradation, a stability enhancing moiety, and a blood-brain barrier shuttle moiety.
[0019] In certain embodiments, the detectable moiety is suitable for detection by positron emission tomography (PET), in particular 11 C. 13 N, 15 O. 18 F, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 44 Sc, 43 Sc, 47 Sc, 124 I, 76 Br, and 82 It may also be a radionuclide selected from the group consisting of Rb.
[0020] In some embodiments, the hexapeptide or hexapeptide derivative is linked to a detectable moiety, and the detectable moiety is a multimodal nanoparticle.
[0021] In certain embodiments, the hexapeptide or hexapeptide derivative is cyclized.
[0022] The present invention further provides a combination of at least two inhibitory peptides as defined above for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject.
[0023] The present invention also provides a pharmaceutical composition comprising at least one inhibitory peptide as defined above and at least one pharma- ceutically acceptable carrier or excipient for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject.
[0024] In certain embodiments, the pharmaceutical composition further comprises at least one additional biologically active agent.
[0025] In certain embodiments, the diagnosis according to the present invention is a diagnosis of an early stage tauopathy.
[0026] In certain embodiments, a diagnostic according to the invention is used to monitor the effectiveness of a tauopathy treatment in a patient.
[0027] In certain embodiments, the tauopathy is selected from the group consisting of Alzheimer's disease (AD), Pick's disease (PD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), age-related tau astrogliopathy (ARTAG), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), subacute sclerosing panencephalitis (SSPE), Guadeloupean parkinsonism, Western pacific amyotrophic lateral sclerosis and parkinsonism-dementia complex (WPC), and / or cerebrovascular disease (CED). The present invention relates to a method for treating or preventing autism, comprising administering to a patient a therapeutically effective amount of ...
[0028] These and other objects, advantages and features of the present invention will become apparent to those skilled in the art after reading the following detailed description of the preferred embodiments. BRIEF DESCRIPTION OF THE DRAWINGS [Brief description of the drawings]
[0029] [Figure 1]Sequence analysis by prediction methods and domains involved in fibril nucleation. PHF6 (306-311 "VQIVYK", β1 in PHF structure) shows strong amyloidogenic properties (blue curve). Secondary structure prediction shows that the entire sequence tends to fold as β-strands (red curve). B Tau fold in PHF (Alzheimer's disease) and NPF (Pick's disease) determined by cryo-EM (see Examples section). In both structures, tau proteins are stacked on top of each other perpendicular to the fibril axis by parallel β-sheet interactions. Tau proteins fold as hairpins stabilized by intramolecular interactions corresponding to interdigitation of amino acid side chains (the end of R1 in Pick's disease is added to domains R3 and R4 in Alzheimer's disease). Peptides involved in the primary and secondary nucleation steps of fibrils are represented as spheres. Primary nucleation is the result of self-assembly of 301VQIVYK306 (dark blue / light blue) into a parallel β-sheet. Secondary nucleation corresponds to interdigitation of 301VQIVYK306 amino acid side chains with 374HKLTF378 (red / orange) in Alzheimer's disease and 336QVEVKS341 (dark green / light green) in Pick's disease. [Diagram 2] Figure 1 shows the prediction by bioinformatics tools of the amyloidogenic properties of the 22 first hexapeptides (red) and 10 additional hexapeptides (green) compared to the PHF6 peptide (1p). The reference peptide 1p is considered 100% amyloidogenic and the scores of the other peptides are normalized as a function of 1p. [Diagram 3] Garnier-Delamarche representation of the 22 initial hexapeptides (red) and 10 additional hexapeptides (green). Peptide fluorescence scores were normalized as a function of the 1p fluorescence score (internal control). The 16p and 9tp peptides (blue) could not be tested at 800 μM as the other peptides due to their low solubility in aqueous media. The % of precipitation and % of fluorescence were measured at a concentration of 288 μM. [Figure 4]Typical polymerization kinetics of 1p in the presence or absence of selected peptides: 1p alone (red); 1p+4p (blue); 1p+23p (green); 1p+1tp (orange). Arrows indicate the time of addition of 5x fibrillation buffer. [ThT]=32mM, PM=800V, slits 03nm. [Diagram 5] Polymerization kinetics of 1p in the presence or absence of selected peptides. (A) Kinetics of 1p alone (red), 1p+1tp (green), and 1tp alone (blue); (B) Kinetics of 1p alone (red), 1p+4tp (green), and 4tp alone (blue); (C) Kinetics of 1p alone (red), 1p+6tp (green), and 6tp alone (blue). [ThT]=32 μM, MW=800V, slit03 nm, [1p]=155 μM, [selected peptide]=310 μM. Arrows indicate the time of addition of 5× fibrillation buffer. [Figure 6] Figure 1 shows the results of the fluorescence intensity and maximum rate of polymerization kinetics of 1p in the presence of selected peptides. The maximum polymerization rate is shown on the left and the fluorescence intensity at 100 min on the right. All results were normalized considering the fluorescence intensity at 100 min and the maximum polymerization rate of 1p as 100%. The peptides of most interest are highlighted by thresholding the plots at 50% for rate and 100% for fluorescence intensity. For each analysis, [ThT]=32 μM, MW=800V, slits 03 nm, [1p]=155 μM, [selected peptide]=310 μM. [Figure 7] Results of the fluorescence intensity and maximum rate of polymerization kinetics of 1p in the presence of peptides with the most interesting inhibitory properties. The maximum polymerization rate is shown on the left and the fluorescence intensity at 100 min on the right. All results were normalized by considering the fluorescence intensity at 100 min and the maximum polymerization rate of 1p as 100%. For each analysis, [ThT]=32 μM, MW=800V, slits 03 nm, [1p]=155 μM, [selected peptide]=310 μM. [Figure 8]Figure 1 shows the effect of 6tp (purple) on the in silico simulated core structure of PHF. 301VQIVYK306 (dark blue / light blue) self-assembles as a parallel β-sheet and interacts with 374HKLTF378 (red / orange) through amino acid side chain interdigitation. The number of 6tp peptides tested varies from 1 (stoichiometry 0.25, panel II) to 4 (stoichiometry 1, panel V). The 301VQIVYK306 / 374HKLTF378 structure is affected from stoichiometry 0.25 and completely unstable at stoichiometry 0.5. [Figure 9] FIG. 1 shows in silico predictions of the interactions of 4tp with free tau protein (R3 / R4 repeats) (A) and with the PHF structure (B). [Figure 10] (A) Analysis of the effect of 100 μM of three peptides classified as "therapeutic" (hexapeptides 1tp, 4tp, 6tp) and two peptides classified as "amyloidogenic" (hexapeptides 7tp and 1p) on the proliferation of cells of the neuroblastoma line SH-SY5Y after 24 h treatment in 1×DMEM medium, 8% serum. (B) i) Cell viability measured using the MTT test after 24 and 48 h and ii) cell viability measured by cell count after 24 and 72 h of peptide treatment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] definition Throughout this specification, several terms are used which are defined in the following paragraphs.
[0031] As used herein, the term "subject" refers to a human or other mammal, including an experimental animal (e.g., primates, mice, rats, rabbits, dogs, cats, horses, cows, goats, pigs, camels, etc.), who may or may not have a disease or disorder, particularly a tauopathy. A non-human subject may be a transgenic or otherwise modified animal. In many embodiments of the invention, the subject is a human. In such embodiments, the subject is often referred to as an "individual" or "patient." The terms "individual" and "patient" do not denote a particular age. The term "patient" refers more particularly to an individual suffering from a disease or disorder, particularly a tauopathy.
[0032] The terms "tau" and "tau protein" are used interchangeably herein. They refer to the human protein encoded by a single gene, MAPT (microtubule-associated protein tau), which maps to chromosome 17q21.31. These terms include any one of six highly soluble protein isoforms produced by alternative splicing in the adult human brain. The terms "abnormal tau", "abnormal form of tau", "pathological tau", and "pathological form of tau" are used interchangeably herein. They refer to any non-functional or deregulated form of tau. Abnormal post-translational modifications are believed to be one of the main causes of this failure. It has been proposed that abnormal phosphorylation (hyperphosphorylation), acetylation, glycosylation, ubiquitination, nitration, proteolytic cleavage (truncating), conformational changes, and some other modifications cause the loss of normal function of tau protein and the acquisition of pathological characteristics. Loss of function or deregulation of tau protein results in its detachment from the microtubules to which it is normally attached. Genetic, pathological, and biochemical analyses have revealed that abnormal tau protein plays a major role in the pathogenesis of all tauopathies.
[0033] As used herein, the term "tauopathy" has its art-understood meaning and refers to a group of clinically, biochemically, and morphologically heterogeneous neurodegenerative diseases characterized by abnormal tau deposition. Several lines of evidence suggest that tau aggregation is central to the neurodegenerative process in tauopathies. In tauopathies, soluble tau is detached from microtubules to form abnormal aggregated fibrillar assemblies of hyperphosphorylated tau. Several neuropathological phenotypes are distinguished based on different anatomical regions involved, cell types, and the presence of different isoforms of tau in the pathological deposits. The term "primary tauopathy" refers to disorders in which tau protein deposition is a major feature. The term "secondary tauopathy" refers to tau pathology that is believed to have other diverse driving forces (e.g., amyloid, aging, trauma, genetics, infectious diseases, toxins, autoimmune diseases, and other unknown factors). The nomenclature of primary tauopathies overlaps with the modern classification of frontotemporal lobar degeneration (FTLD). In the adult human brain, six tau isoforms are expressed that differ by the presence or absence of one or two N-terminal inserts and the presence or absence of the second of four semi-conserved repeats. As a result, half of the tau isoforms have three repeats (3R tau) and the other half of the isoforms have four repeats (4R tau). Tauopathies can be characterized based on the isoform composition of their fibrils, since in tauopathies the ratio of 3R tau / 4R tau differs and depends on the disorder. Thus, tauopathies have been classified into different groups: "3R tauopathies" where 3R tau predominates, "4R tauopathies" where 4R predominates, and "mixed 3R / 4R tauopathies" where the ratio of 3-repeat (3R) tau to 4-repeat (4R) tau is approximately equal. An example of a 3R tauopathy is Pick's disease (PiD), also known as frontotemporal dementia (FTD). Examples of primary 4R tauopathies include progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), and age-related tau astrogliopathy (ARTAG).Examples of primary mixed 3R / 4R tauopathies include frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17); subacute sclerosing panencephalitis (SSPE), also known as Dawson's disease. Other examples of primary mixed 3R / 4R tauopathies include geographically isolated tauopathies, such as Guadeloupe-type parkinsonism, Western Pacific amyotrophic lateral sclerosis and parkinsonism-dementia complex (ALS / PDC), and Northern Uganda nodding syndrome. Examples of secondary mixed 3R / 4R tauopathies include Alzheimer's disease (AD), which is a tauopathy secondary to amyloid deposition; chronic traumatic encephalopathy (CTE), also known as pugilistic dementia, which is secondary to trauma; Huntington's disease (HD); Niemann-Pick disease type C (NPC); Down's syndrome; and postencephalitic parkinsonism (PEP). Other secondary tauopathies include myotonic dystrophies (types 1 and 2).
[0034] As used herein, the term "disorders associated with abnormal tau aggregation" includes any disease or clinical condition that is not defined as a tauopathy, but is a disorder in which abnormal tau deposition is present. Such diseases include, but are not limited to, Lewy body disease (LBD), Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, amyotrophic lateral sclerosis, non-Guam motor neuron disease with neurofibrillary tangles, diffuse neurofibrillary tangles with calcifications, Hallervorden-Spatz disease, multiple system atrophy, pallido-ponto-nigral degeneration, Tau panencephalopathy, AD-like with astrocytes, certain prion diseases, and certain prion diseases. and LRRK2 mutations, familial British dementia, familial Danish dementia, neurodegeneration with brain iron accumulation, SLC9A6-associated mental retardation, white matter tauopathy with globular glial inclusions, traumatic stress syndrome, epilepsy, hereditary cerebral hemorrhage with amyloidosis (Dutch type), mild cognitive impairment (MCI), multiple sclerosis, Parkinson's disease, atypical parkinsonism, HIV-associated dementia, adult-onset diabetes mellitus, senile cardiac amyloidosis, endocrine tumors, glaucoma, ocular amyloidosis, primary retinal degeneration, macular degeneration (such as age-related macular degeneration (AMD)), optic nerve drusen, optic neuropathy, optic neuritis, and lattice dystrophies.
[0035] As used herein, the term "inhibit" means to prevent something from happening, to delay the occurrence of something happening, and / or to reduce the degree or likelihood of something happening. Thus, the terms "inhibiting abnormal tau aggregation" and "inhibiting the formation of abnormal tau aggregates" are used interchangeably herein and are intended to encompass preventing, delaying, and / or reducing the likelihood of the occurrence of abnormal tau aggregation, as well as reducing the degree of abnormal tau aggregates.
[0036] The term "treatment" is used herein to characterize a method or process that aims to (1) delay or prevent the onset of a disease, disorder, or condition (here, a tauopathy); (2) slow or stop the progression, progression, or deterioration of a disease, disorder, or condition; (3) bring about an improvement in the symptoms of a disease, disorder, or condition; or (4) cure a disease, disorder, or condition. Treatment may be administered for therapeutic action after the onset of a disease, disorder, or condition. Alternatively, treatment may be administered for prophylactic or preventative action before the onset of a disease, disorder, or condition. In this case, the term "prevention" is used.
[0037] The term "diagnosis" as used herein includes the assessment of a subject's susceptibility to a disease (here, a tauopathy), the determination of whether a subject currently has the disease, and the prognosis of a subject suffering from the disease. As will be understood by those skilled in the art, such assessment is preferably accurate, but usually may not be accurate for 100% of the subjects to be diagnosed. However, the term requires that a statistically significant portion of subjects can be identified as suffering from or predisposed to the disease. Whether a portion is statistically significant can be easily determined by those skilled in the art using several well-known statistical evaluation tools, such as determining confidence intervals, determining p-values, Student's t-test, Mann-Whitney test, etc. For details, see Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York, 1983. Preferred confidence intervals are at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%. The p-value is preferably 0.2, 0.1, or 0.05. The terms "susceptibility," "proneness," and "predisposition" are used interchangeably herein and refer to a higher than normal probability of developing a disease (here, a tauopathy).
[0038] The terms "labeled" and "labeled with a detectable agent or moiety" are used interchangeably herein to specify that an entity (e.g., an inhibitory peptide of the present invention) can be visualized, for example, after binding to another entity (e.g., a PHF6 peptide or an abnormal tau protein). Preferably, the detection agent or moiety is selected to generate a signal that can be measured and whose intensity is related (e.g., proportional) to the amount of bound entity. A wide variety of systems for labeling and / or detecting peptides are well known in the art. Labeled peptides can be prepared by incorporation or conjugation of a label that is directly or indirectly detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, chemical, or other means. Suitable detectable agents include, but are not limited to, radionuclides, fluorophores, chemiluminescent agents, microparticles, enzymes, colorimetric labels, magnetic labels, haptens, molecular beacons, and aptamer beacons.
[0039] A "pharmaceutical composition" is defined herein to comprise an effective amount of at least one inhibitory peptide described herein, and at least one pharma- ceutically acceptable carrier or excipient.
[0040] As used herein, the term "effective amount" refers to any amount of a compound (e.g., an inhibitory peptide), agent, or composition sufficient for its intended purpose, e.g., to achieve a desired biological, diagnostic, or medical response in a cell, tissue, system, or subject. An effective amount of an inhibitory peptide is an amount that is capable of inducing a measurable amount of a desired result, e.g., inhibition of abnormal tau aggregation or cytotoxicity, in the case of a diagnostic assay, an amount that is capable of detecting a target of interest, or in the case of a method of treatment, an amount that is capable of measurably reducing or ameliorating the symptoms of the disease or condition being treated.
[0041] As used herein, the term "pharmaceutical acceptable carrier or excipient" refers to a carrier medium that does not interfere with the effectiveness of the biological activity of the active ingredient and is not excessively toxic to the host at the concentration administered. This term includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonicity agents, and adsorption retardants, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art (see, for example, "Remington's Pharmaceutical Sciences", EW Martin, 18th Edition, 1990, Mack Publishing Co.: Easton, PA, which is incorporated herein by reference in its entirety). Preferably, the pharmaceutical carrier or excipient is acceptable in human medicine. In certain embodiments, the pharmaceutical acceptable carrier or excipient is a veterinary acceptable carrier or excipient.
[0042] The terms "approximately" and "about," when used herein in reference to numerical values, generally include numerical values within a range of 10% in either direction (greater or less than that numerical value) unless otherwise specified or otherwise apparent from the context (e.g., where such numerical value would exceed 100% of possible values).
[0043] DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS As mentioned above, the present invention provides hexapeptide sequences and inhibitory peptides for use in both the diagnosis and treatment of tauopathies and disorders associated with abnormal tau aggregation.
[0044] I - Inhibitory peptides, hexapeptides, and hexapeptide-based molecules When functional, tau is linked to microtubules via its repeat domains (R1, R2, R3, and R4). 306 VQIVYK 311, SEQ ID NO:2) is an integral part of the R3 domain and is therefore not accessible under normal conditions (i.e. in the absence of disease or pre-disease conditions). Loss of function or deregulation (such as phosphorylation) of tau protein, and thus its detachment from microtubules, is recognized as a phenomenon responsible for the pathogenesis of tauopathies. When abnormal tau protein is found free in the cytoplasm, the PHF6 peptide becomes accessible to the inhibitory peptides described herein.
[0045] The term "inhibitory peptide" as used herein refers to a molecule consisting of or comprising a hexapeptide or a hexapeptide derivative that reduces, inhibits, or prevents the self-association process of abnormal tau protein, particularly the abnormal tau self-association process involving PHF6 peptide. In certain embodiments, the term "inhibitory peptide" refers to a molecule consisting of or comprising a hexapeptide or a hexapeptide derivative that reduces, inhibits, or prevents the interaction of PHF6 peptide in abnormal tau protein. The term "inhibitory peptide" also refers to a molecule consisting of or comprising a hexapeptide or a hexapeptide derivative that reduces, inhibits, or prevents the self-association process of PHF6 peptide in vitro. The hexapeptides and hexapeptide derivatives provided herein are L-hexapeptides, i.e., peptides consisting of six L-amino acid residues. The phrase "inhibitory peptides comprising hexapeptides" means that the inhibitory peptide is composed of the amino acid sequence of a hexapeptide, and the hexapeptide is extended by several amino acids at one or both ends of its termini. For example, the hexapeptide may be extended by a total of 1, 2, 3, 4, 5, 6, 7, or 8 amino acid residues, which do not alter the inhibitory properties of the hexapeptide.
[0046] 1. L-Hexapeptide Sequence The L-hexapeptide according to the invention consists of one of the amino acid sequences shown in Table 1 below.
[0047] [Table 1]
[0048] Thus, the inhibitory peptides disclosed herein consist of or include a hexapeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 to 28 and 55 to 56. In other words, the inhibitory peptides described herein include hexapeptide 3p (SEQ ID NO: 5), 3p inv (SEQ ID NO: 17), 4p (SEQ ID NO: 6), 4p inv (SEQ ID NO: 18), 5p (SEQ ID NO: 7), 5p inv (SEQ ID NO: 19), 6p (SEQ ID NO: 8), 6p inv (SEQ ID NO: 20), 8p (SEQ ID NO: 9), 8p inv (SEQ ID NO: 21), 9p (SEQ ID NO: 10), 9p inv (SEQ ID NO: 22), 13p (SEQ ID NO: 11), 13p inv (SEQ ID NO: 23), 14p (SEQ ID NO: 12), 14p inv (SEQ ID NO: 24), 23p (SEQ ID NO: 13), 23p inv (SEQ ID NO: 25), 1tp (SEQ ID NO: 14), 1tp inv (SEQ ID NO: 26), 4tp (SEQ ID NO: 15), 4tp inv (SEQ ID NO: 27), 6tp (SEQ ID NO: 16), 6tp inv (SEQ ID NO:28), 0tp inv (SEQ ID NO: 55), and 3tp inv (SEQ ID NO: 56).
[0049] However, in a preferred embodiment, the inhibitory peptides disclosed herein consist of or comprise hexapeptides identified by the inventors as weakly amyloidogenic or non-amyloidogenic (compared to the PFH6 peptide) and / or weakly aggregating or non-aggregating. The term "weakly amyloidogenic or non-amyloidogenic" used herein to characterize hexapeptides refers to hexapeptides that do not form or have no tendency to form fibrils, particularly compared to the PHF6 peptide. The term "weakly aggregating or non-aggregating" used herein to characterize hexapeptides refers to hexapeptides that do not form or have no tendency to form self-aggregates, particularly compared to the PHF6 peptide. Thus, in a preferred embodiment, the inhibitory peptides described herein consist of hexapeptides 3p (SEQ ID NO: 5), 4p (SEQ ID NO: 6), 4p inv (SEQ ID NO: 18), 5p (SEQ ID NO: 7), 5p inv (SEQ ID NO: 19), 6p (SEQ ID NO: 8), 8p (SEQ ID NO: 9), 8p inv (SEQ ID NO: 21), 9p (SEQ ID NO: 10), 9p inv (SEQ ID NO: 22), 13p (SEQ ID NO: 11), 13p inv (SEQ ID NO: 23), 14p (SEQ ID NO: 12), 14p inv (SEQ ID NO: 24), 23p (SEQ ID NO: 13), 23p inv (SEQ ID NO: 25), 1tp (SEQ ID NO: 14), 1tp inv (SEQ ID NO: 26), 4tp (SEQ ID NO: 15), 4tp inv (SEQ ID NO: 27), 6tp (SEQ ID NO: 16), 6tp inv (SEQ ID NO:28), 0tp inv (SEQ ID NO: 55), and 3tp inv (SEQ ID NO: 56). In particular, the inhibitory peptide consists of or comprises any one of the hexapeptides 3p, 4p, 5p, 6p, 8p, 9p, 13p, 14p, 23p, 1tp, 4tp, 6tp, 0tp inv , 1tp inv , and 3tp invor any one of the hexapeptides 4p, 5p, 8p, 9p, 13p, 14p, 23p, 1tp, 4tp, and 6tp.
[0050] In certain embodiments, the inhibitory peptides described herein include hexapeptides 3p (SEQ ID NO:5), 4p (SEQ ID NO:6), 4p inv (SEQ ID NO: 18), 5p (SEQ ID NO: 7), 5p inv (SEQ ID NO: 19), 6p (SEQ ID NO: 8), 8p (SEQ ID NO: 9), 8p inv (SEQ ID NO: 21), 9p (SEQ ID NO: 10), 13p (SEQ ID NO: 11), 14p (SEQ ID NO: 12), 14p inv (SEQ ID NO: 24), 23p inv (SEQ ID NO: 25), 1tp (SEQ ID NO: 14), 1tp inv (SEQ ID NO: 26), 4tp (SEQ ID NO: 15), 4tp inv (SEQ ID NO:27), 6tp inv (SEQ ID NO:28), 0tp inv (SEQ ID NO: 55), and 3tp inv (SEQ ID NO: 56).
[0051] In certain preferred embodiments, the inhibitory peptide for use in the method for diagnosing and / or treating tauopathy according to the invention consists of or comprises a hexapeptide identified by the inventors as effectively inhibiting the self-association process of the PHF6 peptide in vitro. Thus, in certain preferred embodiments, the inhibitory peptide for use in the method according to the invention is hexapeptide 4p (SEQ ID NO: 6), 4p inv (SEQ ID NO: 18), 5p (SEQ ID NO: 7), 5p inv (SEQ ID NO: 19), 1tp (SEQ ID NO: 14), 1tp inv (SEQ ID NO: 26), 4tp (SEQ ID NO: 15), 4tp inv (SEQ ID NO: 27), 6tp (SEQ ID NO: 16), 6tp inv (SEQ ID NO:28), 0tp inv (SEQ ID NO: 55), and 3tp inv(SEQ ID NO: 56). In particular, the inhibitory peptide is any one of the hexapeptides 4p, 5p, 1tp, 4tp, and 6tp, or any one of the hexapeptides 1tp, 4tp, 6tp, 0tp inv , 1tp inv , and 3tp inv In certain embodiments, the inhibitory peptide consists of or comprises any one of the hexapeptides 1tp and 6tp.
[0052] In certain embodiments, the hexapeptides are modified to include terminal modifications, such as acetylation and amidation. Thus, the C-terminus of the hexapeptides described herein may be amidated and / or the N-terminus may be acetylated. For example, hexapeptide 3p (SEQ ID NO:5) is represented as Ac-VKYQVI-NH2 when N-acetylated and C-amidated.
[0053] In certain embodiments, the hexapeptide is in a salt form known in the art, particularly a pharma- ceutically acceptable salt. As used herein, the term "pharma-ceutically acceptable salt" refers to a salt of a hexapeptide that retains the biological activity of the parent hexapeptide and is biologically or otherwise undesirable. Examples of pharma-ceutically acceptable salts include, but are not limited to, hydrochloride, acetate, TFA salt, and sodium chloride salt.
[0054] 2. L-Hexapeptide Derivatives The present invention also provides L-hexapeptide derivatives. In certain embodiments, the L-hexapeptide derivatives according to the invention consist of one of the amino acid sequences shown in Table 1, which comprises a single conservative amino acid substitution. In other embodiments, the L-hexapeptide derivatives according to the invention consist of one of the amino acid sequences shown in Table 1, which comprises a conservative amino acid substitution at two of positions 1, 3, and 5, or at two of positions 2, 4, and 6.
[0055] As used herein, the term "conservative amino acid substitution" refers to the replacement of an amino acid with another amino acid without changing the overall conformation and function of the hexapeptide, and more specifically refers to the replacement of an amino acid residue with an amino acid residue having similar properties (e.g., polarity, hydrogen bonding ability, acidity, basicity, shape, hydrophobicity, aromaticity, etc.). The meaning of conservative amino acid substitution, as well as amino acids having similar properties, is well known in the art. For example, in the context of the present invention, the hydrophobic aliphatic amino acid valine (V) can be replaced by alanine (A), leucine (L), or isoleucine (I); the basic amino acid lysine (K) can be replaced by arginine (R) or histidine (H), in particular arginine (R); the hydrophobic aliphatic amino acid isoleucine (I) can be replaced by valine (V), leucine (L), or alanine (A); the neutral polar amino acid glutamine (Q) can be replaced by asparagine (N), serine (S), or threonine (T), in particular asparagine (N); and the aromatic amino acid tyrosine (Y) can be replaced by tryptophan (W) or phenylalanine (F).
[0056] As used herein, the term "position 1, 2, 3, 4, 5, or 6" refers to the first, second, third, fourth, fifth, or sixth amino acid residue positions of a hexapeptide (or hexapeptide derivative) when the sequence is presented from left to right.
[0057] Thus, the inhibitory peptides disclosed herein consist of or comprise a hexapeptide derivative having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-28 and 55-56, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3, and 5 or two of positions 2, 4, and 6.
[0058] In certain embodiments, the inhibitory peptides described herein consist of or comprise a hexapeptide derivative having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-16, 18-19, 21-28, and 55-56, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3, and 5 or at two of positions 2, 4, and 6. In particular, the inhibitory peptides may consist of or comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-16, 26, and 55-56, or may consist of or comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-7 and 9-16, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3, and 5 or at two of positions 2, 4, and 6.
[0059] In certain embodiments, the inhibitory peptides described herein consist of or comprise a hexapeptide derivative having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-12, 14-16, 18-19, 21, 24-28, 55, and 56, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3, and 5 or two of positions 2, 4, and 6.
[0060] In certain embodiments, the inhibitory peptides described herein consist of or comprise a hexapeptide derivative having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-7, 14-16, 18-19, 26-28, 55, and 56, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3, and 5 or at two of positions 2, 4, and 6. In particular, the inhibitory peptides may consist of or comprise a hexapeptide derivative having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-7 and 14-16, or from the group consisting of SEQ ID NOs: 14-16, 26, 55, and 56, wherein the amino acid sequence comprises a single conservative amino acid substitution, or wherein the amino acid sequence comprises conservative amino acid substitutions at two of positions 1, 3, and 5 or at two of positions 2, 4, and 6. In certain embodiments, the inhibitory peptide consists of or comprises a hexapeptide derivative having the amino acid sequence SEQ ID NO:14 or SEQ ID NO:16, wherein the amino acid sequence contains a single conservative amino acid substitution, or wherein the amino acid sequence contains conservative amino acid substitutions at two of positions 1, 3, and 5 or two of positions 2, 4, and 6.
[0061] In certain embodiments, the hexapeptide derivatives are modified as described above to include terminal modifications, such as acetylation and amidation.
[0062] In certain embodiments, the hexapeptide derivative is in the form of a pharma- ceutically acceptable salt, as described above.
[0063] 3. Hexapeptide-based molecules In certain embodiments, the inhibitory peptide used in the method for diagnosing and / or treating tauopathy according to the present invention consists of or comprises a hexapeptide-based molecule. As used herein, the term "hexapeptide-based molecule" refers to a hexapeptide or hexapeptide derivative as defined herein that has been modified, e.g. chemically modified, but retains its inhibitory activity against the interaction of PHF6 peptide in abnormal tau protein. The term "hexapeptide-based molecule" also refers to a hexapeptide or hexapeptide derivative as defined herein that has been modified, e.g. chemically modified, but retains its inhibitory activity against the self-association process of PHF6 peptide in vitro. In certain embodiments, the modification is that the hexapeptide or hexapeptide derivative as defined herein is linked to a heterologous moiety.
[0064] As used herein, the term "link" and related terms, such as "link" and "connected," refer to a connection between two groups or molecules (e.g., between a hexapeptide and a heterologous moiety). The connection can be achieved by covalent bonding (by a covalent chemical bond) or non-covalent bonding, for example by physical forces, such as electrostatic bonds, hydrogen bonds, ionic bonds, van der Waals bonds, or hydrophobic / hydrophilic interactions. The connection may be direct or indirect. If indirect, the connection may be through a linker or spacer. The terms "linker" and "spacer" are used interchangeably herein and refer to a molecule that joins two other molecules (e.g., a hexapeptide and a heterologous moiety) either covalently or non-covalently. Linkers and spacers used in peptide modifications, particularly peptidic linkers and spacers, are known in the art. The term "heterologous moiety," as used herein, is synonymous with the term "conjugated moiety" and refers to any molecule (chemical or biochemical, naturally occurring, or non-encoded) that is distinct from the hexapeptides described herein. Heterologous moieties to be linked to the hexapeptides or hexapeptide derivatives disclosed herein are preferably selected for their ability to optimize the potency, pharmacokinetic behavior, stability, and / or other biological, physical, and chemical properties of the hexapeptide or hexapeptide derivative, or to confer new physicochemical or functional properties to the hexapeptide or hexapeptide derivative. Thus, for example, heterologous moieties may be selected based on their ability to (1) increase the stability of the hexapeptide or hexapeptide derivative, e.g., by reducing susceptibility to proteolysis, (2) increase cell permeability, (3) confer detectability properties, and (4) target the hexapeptide or hexapeptide derivative to a given cellular target or environment, etc.Examples of heterologous moieties suitable for linking to the hexapeptides or hexapeptide derivatives described herein include, but are not limited to, detectable moieties, cell-penetrating agents, stability-enhancing moieties, blood-brain barrier shuttle moieties, tags that allow for cellular degradation, and any other molecule or moiety capable of imparting desirable properties to the hexapeptide or hexapeptide derivative.
[0065] a. Detectable moieties. The heterologous moiety may be a detectable moiety or a detectable label. Thus, in certain embodiments, the inhibitory peptides for use in the methods for diagnosing and / or treating tauopathies according to the present invention consist of or comprise a hexapeptide or hexapeptide derivative described herein that is labeled with a detectable agent or moiety. The detectable moiety may be selected from among radioisotopes, antigenic determinants, enzymes, nucleic acids available for hybridization, chromophores, fluorophores, chemiluminescent molecules, electrochemically detectable molecules, and molecules that produce a change in fluorescence polarization or a change in light scattering.
[0066] Preferably, the detectable moiety is suitable for detection by diagnostic imaging techniques, such as fluorescence, positron emission tomography (PET), magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT / CT), in vivo laser scanning microscopy, endoscopy, and radioimaging. Useful detectable labels include, but are not limited to, radionuclides, radiocontrast agents, paramagnetic ions, metals, biological tags, fluorescent labels, near infrared labels, chemiluminescent labels, ultrasound contrast agents, and photoactive agents, depending on the technique or combination of imaging techniques used. Such diagnostic agents are well known in the art, and any such known diagnostic agent can be used. Non-limiting examples of diagnostic agents include radionuclides, such as 110 In, 111 In, 177 Lu, 18 F, 52 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga,44 Sc、 43 Sc、 47 Sc、 86 Y、 90 Y、 89 Zr、 94m Tc、 94 TC、 99m Tc、 120 I、 123 I、 124 I、 125 I、 131 I、 154~158 Gd、 32 P、 11 C、 13 N、 15 O、 186 Re、 188 Re、 51 Mn、 52 mMn、 55 Co、 72 As、 75 Br、 76 Br、 82 mRb、 83The paramagnetic ions may include Sr, or other gamma-, beta-, or positron-emitting nuclei. Suitable paramagnetic ions may include chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III), or erbium (III). Metallic contrast agents may include lanthanum (III), gold (III), lead (II), or bismuth (III). Ultrasound contrast agents may include liposomes, e.g., gas-filled liposomes. Radiopaque diagnostic agents may be selected from barium compounds, gallium compounds, and thallium compounds. A wide variety of fluorescent labels are known in the art, including, but not limited to, fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, and fluorescamine. Chemiluminescent labels used may include luminol, isoluminol, aromatic acridinium ester, imidazole, acridinium salt, or oxalate ester.
[0067] In certain preferred embodiments, the hexapeptides or hexapeptide derivatives described herein are labeled with a detectable moiety suitable for detection by positron emission tomography (PET), one of the major brain imaging techniques. In such embodiments, the inhibitory peptide is 11 C. 13 N, 15 O. 18 F, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 44 Sc, 43 Sc, 47 Sc, 124 I, 76 Br, and 82 Rb, in particular62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 44 Sc, 43 Sc, and 47 The present invention may consist of or comprise a hexapeptide or hexapeptide derivative as described herein, labelled with any one of Sc.
[0068] In certain embodiments, a chelator can be attached to the hexapeptide or hexapeptide derivative and used to chelate a detectable moiety, such as a radionuclide. Exemplary chelators include, but are not limited to, DTPA (such as Mx-DTPA), DO3A, DOTA, EDTA, TETA, EHPG, HBED, NETA, NOTA, DOTMA, DFO, TETMA, PDTA, TTHA, LICAM, HYNIC, and MECAM. Conjugation methods and the use of chelators to attach metals or other ligands to proteins and peptides are well known in the art.
[0069] In certain embodiments, the hexapeptides or hexapeptide derivatives described herein are attached to nanoparticles suitable for use in medical imaging (Kalra et al., "10. Nanoparticles in Medical Imaging," Nanoparticles in Analytical and Medical Devices, 2021, pp. 175-210). As used herein, the term "nanoparticle" is meant to include particles, spheres, capsules, and other structures having an average diameter of less than 1 micrometer. Preferred particles have a particle size of up to about 50 nm, or up to about 10 nm.
[0070] Suitable nanoparticles include quantum dots, i.e. brightly colored fluorescent nanocrystals whose physical dimensions are small enough that quantum confinement effects result in unique optical and electronic properties. Other suitable nanoparticles are optically detectable nanoparticles, such as metal nanoparticles. Metals used to form nanoparticles include, but are not limited to, Ag, Au, Cu, Al, Fe, Co, Ni, Ru, Rh, Pd, and Pt, or oxides thereof. In particular, metals may include Fe or iron oxide. Additional surface functional layers may be added or formed in combination with the metal core material. Such functional layers can include, but are not limited to, Ag oxide, Au oxide, SiO2, Al2O3, Si3N4, TiO2, ZnO, ZnO2, HfO2, Y2O3, tin oxide, antimony oxide, iron oxide, and other oxides; chlorine or chloride doped Ag, chlorine or chloride doped Au, ethylene and chlorotrifluoroethylene (ECTFE), poly(ethylene-co-butyl acrylate-co-carbon monoxide) (PEBA), poly(allylamine hydrochloride) (PAH), polystyrene sulfonate (PSS), polytetrafluoroethylene (PTFE), polyvinyl alcohol (PVA), polyvinyl chloride (PVC), polyvinyldene fluoride (PVDF), polyvinylpyrrolidone (PVP), and other polymers; stacked multilayers of at least two layers including the metallic and non-metallic layers listed above, and the like. In some embodiments, the metal core may be Au, Ag, Fe, Ti, Ni, Cr, Pt, Ru, NiCr alloy, NiCrN, PtRh alloy, CuAuCo alloy, IrRh alloy, and / or WRe alloy. The metals used should be biocompatible. Other suitable nanoparticles include magnetic nanoparticles. The term "magnetic nanoparticles" refers to magnetically responsive nanoparticles that include one or more metals or their oxides or hydroxides. For example, superparamagnetic iron oxide (SPIO) is a type of MR contrast agent composed of nanoparticles of iron oxide crystals coated with carbohydrates.As is known in the art, optically detectable metal nanoparticles or quantum dots, when administered systemically to a subject, can be detected in vivo using magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), nuclear magnetic resonance imaging (NMR), multimodal imaging, fluorescence, positron emission tomography (PET), near infrared (NIR) imaging, X-ray imaging, and computed tomography (CT).
[0071] In certain embodiments, the nanoparticle is a multimodal nanoparticle, particularly suitable for imaging brain tissue. The term "multimodal nanoparticle" as used herein refers to a nanoparticle that can be used in combination with more than one bioimaging technique. A multimodal nanoparticle may have multiple moieties that behave as different contrast agents for different imaging techniques. Multimodal imaging or multiplex imaging refers to the simultaneous generation of signals from more than one imaging technique. For example, a multimodal nanoparticle can be developed using a combination of optical, magnetic, and / or radioactive reporters that are detected by SPECT, MRI, and PET. Multimodal nanoparticles are known in the art (Jarzyna et al., Rev. Nanomed. Nanobiotechnol., 2010, 2(2):138-150; Huang et al., Dalton Trans., 2011, 40(23):6087-6103; Madru et al., J. Nucl. Med., 2012, 53(3):459; Tang et al., Nanomedicine, 2015, 10(8):1343-1359; Burke et al., Philos. Trans. A Math. Phys. Eng. Sci., 2017, 375(2107):20170261; Tang, "PET / SPECT / MRI multimodal nanoparticles," "Design and Applications of Nanoparticles in Biomedical (In: Imaging, Bulte and Modo (eds.), 2017, pp. 205-228). In particular, nanoparticle-based radiotracers have shown promise as multimodality probes for SPECT / MRI and PET / MRI.
[0072] b. Cell-penetrating agents. The heterologous moiety may be a cell-penetrating agent, e.g., a cell-penetrating peptide (i.e., a CPP). Thus, in certain embodiments, an inhibitory peptide according to the present invention consists of or comprises a hexapeptide or hexapeptide derivative described herein, linked directly or indirectly to a cell-penetrating agent, e.g., a cell-penetrating peptide.
[0073] As used herein, the term "cell penetrating peptide" refers to short peptidic agents (generally less than 30 amino acids) that enhance the translocation of any attached hexapeptide across the cell membrane. Typically, cell penetrating peptides belong to three different classes: polycationic CPPs, which have an amino acid composition that includes positively charged amino acid residues, such as lysine or arginine, in high relative abundance; amphipathic CPPs, which have a sequence that includes an alternating pattern of polar / charged and non-polar / hydrophobic amino acid residues; and hydrophobic CPPs, which have a sequence that includes only non-polar residues with a low net charge or have hydrophobic amino acid groups that are important for cellular uptake.
[0074] Examples of typical CPPs suitable for use in the practice of the present invention include, but are not limited to, the following: polyarginine (polyARG) (n R's, where n is an integer, e.g., 4 < n < 17, and in particular 9 arginines, 8 arginines, 6 arginines), polyLYS (n K's, where n is an integer, e.g., 4 < n < 17), D-polyARG (n R's, where n is an integer, e.g., 4 < n < 17), D-polyLYS (n K's, where n is an integer, e.g., 4 < n < 17), SynBl, SynB3, penetratin, Drosophila homeotic protein antennapedia (ANTp), PenArg, PenLys, TatP59W, Tat (HIV transcriptional transactivator), Tat(48 - 60), R9-Tat, D-Tat, BMVGag(7 - 25), FHVCoat(35 - 49), HTLV-II Rex(4 - 16), P22 N-Q(4 - 30), pVEC, TP10, PTD-4, PTD-5, Pep-1, Pep-2, Pep-3, E NQ-22, B21 N-(12 - 29), U2AFQ(42 - 153), PRP6(129 - 144), MAP, SBP, FBP, MPG, MPG(ANLS), and REV(34 - 50), which are described in WO 2018 / 005867 pamphlet; and EB1, transportan, p-Antp, hcT(18 - 32), Xentry, KLA seq. Other examples of cell-permeable peptides include the following: W / R, NLS (nuclear localization signal), AlkCWK 18 , DiCWK 18 , DipaLytic, K 16 RGD, Pl, P2, P3, P3a, P9.3, Plae, Kplae, cKplae, MGP, HA2, LARL 46, (LARL)n, Hel-11-7, KK, KWK, RWR, herpesvirus VP22, SCWKn, RGD, MPG, ARF(1-22), BPrPp(1-28), VT5, MAP, SG3, Pep-7, stapled peptides, prenylated peptides, pepducin, R6W3, arginine-rich peptide-like (Arg-X-Arg)n peptides, where X is a common carbon chain spacer, proline-rich peptides (Schwartz et al., Curr. Opin. Mol. Ther. 2000, 2(2):162-7; Lee et al., Methods Mol. Biol. 2013, 991:281-92; Bechara et al., FEBS Lett. 2013, 587(12):1693-1702; Di Pisa et al., J. Pept. Sci., 2015, 21(5):356-369; Guo et al., Biomed. Rep., 2016, 4(5):528-534). According to a particular embodiment, the cell-permeable moiety is as described in Svensen et al., 2012, Trends in Pharmacological Sciences, 33(4):186-192.
[0075] In certain embodiments, the cell-penetrating peptidic moiety linked to the hexapeptide or hexapeptide derivative described herein is a poly-Lys sequence, which upon binding allows targeting of free tau protein in the cytoplasm to the cellular degradation system (such as the proteasome or other).
[0076] In certain embodiments, the CPP is directly coupled to the hexapeptide or hexapeptide derivative. In other embodiments, it is desirable to separate the highly charged CPP from the hexapeptide or hexapeptide derivative with a linker, allowing the hexapeptide to retain its inhibitory activity. Any of a variety of linkers can be used. Suitable linkers include peptidic sequences of 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid residues.
[0077] Another method of enhancing cell permeability of peptides is through N-terminal myristoylation. Thus, in certain embodiments, the inhibitory peptide consists of or comprises a hexapeptide or hexapeptide derivative as described herein linked to a myristoyl group (derived from myristic acid). The myristoyl group is a 14-carbohydrate of a saturated fatty acid (Cl4), which confers sufficient hydrophobicity and affinity for membranes to the peptide, but not enough to permanently anchor the peptide to the membrane. Thus, in general, myristoylation acts as a conformational localization switch, where protein conformational changes affect the affinity of the peptide for membrane attachment. The myristoyl group may be covalently attached via an amide bond to the alpha-amino group of the N-terminal amino acid of the hexapeptide.
[0078] c. Stability enhancing moiety. The heterologous moiety may be a stability enhancing moiety. Thus, in certain embodiments, an inhibitory peptide for use in a method according to the invention consists of or comprises a hexapeptide or hexapeptide derivative described herein, linked directly or indirectly to a stability enhancing moiety.
[0079] As used herein, the term "stability-enhancing moiety" refers to a moiety (molecule) that, when linked to a hexapeptide or hexapeptide derivative described herein, affects its pharmacokinetics, more specifically, it increases the metabolic stability and plasma half-life of the hexapeptide or hexapeptide derivative. The stability-enhancing moiety may also affect the solubility, intestinal permeability, and resistance to proteases of the hexapeptide or hexapeptide derivative, etc. Stability-enhancing moieties include, but are not limited to, carbohydrates (glycans), lipids, such as fatty acids, and water-soluble polymers, such as polyethylene glycol (PEG).
[0080] It is known that the introduction of carbohydrate moieties (glycosylation) can modify the physiological properties of peptides and improve their bioavailability. Glycosylation favorably influences the pharmacokinetic properties of peptides, leading to an increase in their oral absorption and bioavailability. In addition to O-linked and N-linked glycosylation techniques, several chemical and chemoenzymatic methods have been established for the attachment of carbohydrate units to various amino acid residues at the N-terminus of a peptide sequence. The carbohydrate may be a monosaccharide (e.g., glucose, galactose, fructose), a disaccharide (e.g., sucrose, lactose, maltose), an oligosaccharide (e.g., raffinose, stachyose), or a polysaccharide (starch, amylase, amylopectin, cellulose, chitin, callose, laminarin, xylan, mannan, fucoidan, or galactomannan).
[0081] Lipid conjugates of peptides are known to exhibit higher stability and longer plasma half-life. Examples of suitable lipids include, but are not limited to, fatty acids, eicosanoids (e.g., prostaglandins, leukotrienes, thromboxanes), glycerolipids (e.g., mono-, di-, and tri-substituted glycerols), glycerophospholipids (e.g., phosphatidylcholine, phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine), sphingolipids (e.g., sphingosine, ceramide), sterol lipids (e.g., steroids, cholesterol), prenol lipids, saccharolipids, or polyketides, oils, waxes, cholesterol, sterols, fat-soluble vitamins, monoglycerides, diglycerides, triglycerides, or phospholipids. In certain embodiments, the lipid is a fatty acid. A fatty acid is a carboxylic acid with a long aliphatic chain that is either saturated or unsaturated. Preferred fatty acids have an unbranched chain of an even number of carbon atoms, from 4 to 28. Various approaches are available for fatty acid conjugation. Synthesis can be performed such that the fatty acid is conjugated either to the N-terminus or to the side chain of lysine. Cysteine residues of peptides or of linkers or spacers can also be modified with fatty acids to give the corresponding thioester derivatives. The most commonly used fatty acids for lipidation (fatty acid conjugation to peptides) are caprylic acid (C8), capric acid (C10), lauric acid (C12), myristic acid (C14), palmitic acid (C16), and stearic acid (C18).
[0082] Covalent attachment of peptides to water-soluble (or hydrophilic) polymers is known to affect peptide pharmacokinetics, and more particularly increases peptide stability and plasma half-life. Examples of suitable hydrophilic polymers include, but are not limited to, polyethylene glycol, polyvinyl alcohol, other poly(alkylene oxides), such as poly(propylene glycol), poly(oxyethylated polyols), such as poly(oxyethylated glycerol), carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride, and polyamino acids. Linear or branched hydrophilic polymers are contemplated.
[0083] In certain embodiments, PEG, a well-known polymer that has good solubility in many aqueous and organic solvents, exhibits low toxicity and lack of immunogenicity, and is transparent, colorless, odorless, and stable, is preferably used as the hydrophilic polymer. The most common form of PEG is a linear or branched polyether with terminal hydroxyl groups: HO-(CH2-CHO). n The peptide modification can be derivatized with a number of linking moieties to yield methoxyPEG-amine, -maleimide, or -carboxylic acid, and is preferably monofunctional methoxy-PEG (mPEG): CH3O-(CH2CH2O). n The PEG may be -CH2CH2-OH. Preferably, PEG with an average molecular weight of about 5 to about 50 kDa is used for clinically approved pharmaceutical applications. Two or more low molecular weight chains may be added to increase the total molecular weight of the PEG conjugate. PEGylation of peptides is widely known in the state of the art (for a review, see Veronese, Biomaterials, 2001, vol. 22:405-417). PEG can be coupled to various available reactive groups of peptides or linkers, such as lysine, aspartic acid, cysteine, glutamic acid, serine, threonine, N-terminal amine, and C-terminal carboxylic acid, or other specific sites.
[0084] d. Blood-brain barrier shuttle moiety. The heterologous moiety may be a blood-brain barrier shuttle moiety. Thus, in certain embodiments, an inhibitory peptide for use in a method according to the invention consists of or comprises a hexapeptide or hexapeptide derivative as described herein, linked directly or indirectly to a blood-brain barrier shuttle moiety.
[0085] As used herein, the term "blood-brain barrier shuttle moiety" refers to a moiety that, when linked to a hexapeptide or hexapeptide derivative described herein, has the ability to transport the peptide across the blood-brain barrier (BBB) by either active or passive transport mechanisms. The BBB shuttle is a powerful facilitator of drug delivery to the brain. In certain embodiments, the blood-brain barrier shuttle moiety is a BBB shuttle peptide.Examples of suitable BBB shuttle peptides include, but are not limited to, Angiopep-2 (Demeule et al., J. Pharmacol. Exp. Ther., 2008, 324:1064-1072; Demeule et al., J. Neurochem., 2008, 106:1534-1544; Ying et al., Angew. Chem., Int. Ed., 2014, 53:12436-12440); ApoB(3371-3409) (Spencer et al., Proc. Natl. Acad. Sci. USA, 2007, 104:7594-7599; Sorrentino et al., EMBO Mol. Med., 2013, 5:675-690); ApoE(159-167) (Wang et al., Proc. Natl. Acad. Sci. USA, 2013, 110:2999-3004; Bockenhoff et al., J. Neurosci., 2014, 34:3122-3129; Re et al., Nanomedicine, 2011, 7:551-559); peptide-22 (Malcor et al., J. Med. Chem., 2012, 55:2227-2241); THR (Lee et al., Eur. J. Biochem., 2001, 268:2004-2012; Prades et al., Biomaterials, 2012, 33:7194-7205); THR retro-enantiomer (Prades et al., Angew. Chem., Int. Ed., 2015, 54:3967-3972); CRT (Staquicini et al., J. Clin. Invest., 2011, 121:161-173); Leptin30 (Barrett et al., Regul. Pept., 2009, 155:55-61; Liu et al., Biomaterials, 2010, 31:5246-5257); RVG29 (Kumar et al., Nature, 2007, 448:39-43; Kim et al., Mol. Ther., 2010, 18:993-1001; Zadran et al., NeuroMol. Med., 2013, 15:74-81); DCDX (Wei et al., Angew. Chem., Int. Ed., 2015, 54:3023-3027); apamin (Oiler-Salvia et al., Biopolymers, 2013, 100:675-686; Wu et al., Mol. Pharmaceutics, 2014, 11:3210-3222); MiniAp-4 (Oiler-Salvia et al., Angew. Chem., Int. Ed., 2016, 55:572-575); GSH (Gaillard et al., J. Controlled Release, 2012, 164:364-369; Mdzinarishvili et al., Drug Delivery Transl. Res., 2013, 3:309-317; Lee et al., J. Neuroimmunol., 2014, 274:96-101; Lindqvist et al., Mol. Pharmaceutics, 2013, 10:1533-1541); G23 (Georgieva et al., Angew. Chem., Int. Ed., 2012, 51:8339-8342); g7 (Costantino et al., J. Controlled Release, 2005, 108:84-96; Tosi et al., Curr. Med. Chem., 2013, 20:2212-2225; Tosi et al., J. Neural Transm., 2011, 118:145-153; Vilella et al., J. Controlled Release, 2005, 108:84-96; Release, 2014, vol. 174: 195-201); TGN (Li et al., Biomaterials, 2011, vol. 32: 4943-4950; Gao et al., Biomaterials, 2012, vol. 33: 5115-5123; Zhang et al., Biomaterials, 2014, vol. 35: 456-465); TAT(47-57) (Schwarze et al., Science, 1999, vol. 285: 156915-72; Aarts et al., Science, 2002, vol. 298: 846-850; Wang et al., Biomaterials, 2010, vol. 31: 2874-2881); SynBl (Rousselle et al., Mol. Pharmacol., 2000, 57:679-686; Drin et al., J. Biol.Chem., 2003, 278:31192-3120); diketopiperazine (Teixido et al., J. Am. Chem. Soc., 2007, 129:11802-11813; Teixido et al., Biopolymers, 2013, 100:662-674); and PhPro (Arranz-Gibert et al., J. Am. Chem. Soc., 2015, 137:7357-7364), all of which are described in Oiler-Salvia et al., Chem. Soc. Rev., 2016, 45:4690-4707. Other examples of BBB shuttle peptides include, but are not limited to, the BBN shuttle peptides described in Diaz-Perlas et al., Chem. Sci., 2018, 9:8409-8415 and Majerova et al., Molecules, 2020, 25(4):874.
[0086] e. Other heterologous moieties. Other examples of heterologous moieties suitable for attachment to the hexapeptides or hexapeptide derivatives described herein include albumin-binding small molecules, which can indirectly interact with albumin via highly conjugated small molecules to reduce glomerular filtration, improve proteolytic stability, and extend half-life. Other suitable heterologous moieties include, but are not limited to, albumin (particularly human serum albumin or HAS) or IgG fragments (e.g., variable regions, CDRs, or Fc regions), which are known to reduce clearance and extend half-life of peptides. Fusion of peptides to hydrophilic amino acid polymers is also known to extend the half-life of peptides. Hydrophilic amino acid polymers include, but are not limited to, XTEN polymers (non-immunogenic polypeptides consisting of six hydrophilic, chemically stable amino acid residues A, E, G, P, S, and T developed by AMunix) or PAS polymers (polypeptides containing long repeats of the small L-amino acids P, A, and / or S developed by XL-Protein GmbH).
[0087] f. Peptide Modifications. Alternatively or in addition to being linked to a heterologous moiety, the hexapeptides or hexapeptide derivatives described herein can themselves be modified to optimize the potency, pharmacokinetic behavior, stability, and / or other biological, physical, and chemical properties of the hexapeptide.
[0088] For example, the hexapeptides or hexapeptide derivatives disclosed herein may be modified to increase resistance to proteolytic destruction when present in an environment where proteolysis occurs frequently, such as blood. In fact, not a few proteolytic enzymes in blood / plasma, liver, or kidney are exopeptidases, aminopeptidases, and carboxypeptidases, which degrade peptide sequences from the N-terminus and C-terminus. N-terminus and / or C-terminus modifications often improve peptide stability. N-acetylation and C-amidation have been reported to increase resistance to proteolysis in many cases. Other N-terminal modifications include methylation, acylation, and thioglycolic acid amidation.
[0089] In certain embodiments, the hexapeptides or hexapeptide derivatives described herein are modified to include one or two additional amino acid residues at the N-terminal portion to achieve resistance to peptidase cleavage. The additional amino acid residue at position 1 can be selected from the group consisting of D-histidine, desaminohistidine, hydroxyl-histidine, acetyl-histidine, homo-histidine, N-methylhistidine, α-methylhistidine, imidazole acetic acid, or α,α-dimethylimidazole acetic acid (DMIA). The additional amino acid residue at position 2 can be selected from the group consisting of D-serine, D-alanine, valine, glycine, N-methylserine, N-methylalanine, or α-aminoisobutyric acid.
[0090] In certain embodiments, the hexapeptides or hexapeptide derivatives described herein may be modified by the addition of charged amino acids at the C-terminal portion. Such modifications enhance stability and solubility. The terms "charged amino acid" and "charged residue" are used interchangeably herein and refer to amino acids that contain a side chain that is negatively charged (i.e., deprotonated) or positively charged (i.e., protonated) in aqueous solution at physiological pH. One, two, or three (and in some cases more than three) charged amino acids, particularly negatively charged amino acids, may be introduced at the C-terminal position. Negatively charged amino acid residues include aspartic acid, glutamic acid, cysteic acid, homocysteic acid, and homoglutamic acid. Such modifications enhance solubility.
[0091] Alternatively, the hexapeptides or hexapeptide derivatives described herein can be stabilized by cyclization, but cyclization does not seriously impede peptide properties, particularly the ability of the hexapeptide to inhibit, reduce, or prevent PHF6 peptide interactions. Cyclic peptides are polypeptide chains in which the amino and carboxyl termini are linked together by peptide bonds or other covalent bonds to form a cyclic chain. Cyclization can introduce conformational constraints and reduce the flexibility of the peptide, thereby improving stability and permeability. Depending on the functional groups, peptides can be cyclized head-to-tail, head / tail-to-side chain, or side chain-to-side chain. Cyclization can occur by the formation of any one of amides, thioethers, thioesters, ureas, carbamates, sulfonamides, lactams, lactones, and disulfide bridges, etc. For example, the hexapeptides or hexapeptide derivatives described herein can be modified to include amino- and carboxyl-terminal cysteine amino acid residues that facilitate disulfide bond formation. Thus, the hexapeptide or hexapeptide derivative may be modified to include an additional cysteine amino acid residue, near the terminus, but not necessarily at the terminus itself. Alternatively, the cysteine amino acid residue may be located within the terminal five amino acid residues of the hexapeptide or hexapeptide derivative. Disulfide bridges are known to create folding and conformational constraints that can improve the potency, selectivity, and stability of the peptide. In a different method, peptides may be cyclized via a bifunctional agent, such as a dicarboxylic acid (e.g., octanedioic acid), which introduces a link between two functional groups (e.g., free amino, hydroxyl, and thio) of the hexapeptide or hexapeptide derivative. Methods for designing and synthesizing cyclic peptides are well known in the art.
[0092] g. Inhibitory Peptides. As will be appreciated by those skilled in the art, inhibitory peptides for use in the methods of the present invention comprise hexapeptides or hexapeptide derivatives as described herein that have been modified to include one or more of the various heterologous moieties and hexapeptide modifications described herein, so long as such modifications do not significantly affect the functionality of the inhibitory peptide in performing its desired role and in providing its intended diagnostic and / or therapeutic effect. In other words, within a given hexapeptide-based molecule, modifications or combinations of modifications are permissible only to the extent that the resulting peptide retains the inhibitory properties of the starting hexapeptide sequence against the aberrant tau protein self-association process, in particular the assembly of aberrant tau into paired helical fibrils (PHFs) that are dependent on PHF6. Modifications or combinations of modifications of hexapeptides or hexapeptide derivatives as described herein can be experimentally determined to be permissible if the resulting peptide retains the inhibitory properties of the starting hexapeptide sequence or hexapeptide derivative sequence against the self-association process of PHF6 peptide in vitro. In some embodiments, about 100% of the activity is retained in a given assay, while in other embodiments, about 98%, about 95%, about 90%, about 85%, about 80%, about 70%, or about 60% of the activity is retained in an assay.
[0093] Depending on the intended use of the resulting inhibitory peptide, one of skill in the art can easily envision optimized combinations of hexapeptide modifications (i.e., attachment to heterologous moieties and / or hexapeptide modifications). For example, if the inhibitory peptide is intended for use in a method for diagnosing a tauopathy, the hexapeptide-based molecule may preferably comprise a hexapeptide labeled with a detectable moiety, preferably a radionuclide, in particular a radionuclide suitable for detection by PET or multimodal imaging techniques.
[0094] Thus, in certain embodiments, inhibitory peptides for use in methods for diagnosing and treating tauopathies consist of a hexapeptide or hexapeptide derivative as described herein, modified so that the C-terminus is labeled with a detectable moiety, e.g., a radionuclide suitable for detection by PET, and the N-terminus is linked to a stabilizing moiety or a CPP moiety or a BBB shuttle moiety.
[0095] The inhibitory peptides described herein interact specifically with the PHF6 sequence. In particular, the inhibitory peptides described herein bind specifically (i.e., selectively, preferentially) to the PHF6 sequence and not to unintended sequences. The PHF6 sequence to which the inhibitory peptide binds may be a PHF6 peptide in vitro, or may be part of an abnormal tau protein in cell culture or in vivo, where the abnormal tau protein may be in the form of a monomer, small aggregate, oligomer, or fibril. For example, the binding may be 2-fold, 5-fold, 10-fold, 100-fold, 200-fold, 500-fold, or more than 500-fold, or no binding may be detected at all to the unintended target. For example, the specificity of the binding may be determined using conventional methods, such as competitive binding assays or other suitable analytical methods.
[0096] 3. Preparation of L-hexapeptides and hexapeptide-based molecules The hexapeptides, hexapeptide derivatives, and hexapeptide-based molecules disclosed herein can be prepared using any of a variety of art-recognized methods, including chemical synthesis and recombinant expression in a suitable host cell.
[0097] For example, hexapeptides and their derivatives can be prepared using standard chemical methods. Solid-phase peptide synthesis, first reported by RB Merrifield (J. Am. Chem. Soc. 1963, vol. 85:2149-2154), is a rapid and easy method for the synthesis of peptides and peptidic molecules of known short sequence. A review of such solid-phase techniques is given, for example, in "Solid Phase Peptide Synthesis" (Methods in Enzymology, GB Fields (ed.), 1997, Academic Press: San Diego, Calif., which is incorporated herein by reference in its entirety). Most of these synthetic procedures involve the sequential addition of one or more amino acid residues or suitably protected amino acid residues to a growing peptide chain. After assembly, the desired peptide can be cleaved from the solid support, precipitated, and the resulting free peptide analyzed and / or purified as required. For example, solution methods described in "The Proteins" (Vol. II, 3rd Edition, H. Neurath et al. (eds.), 1976, Academic Press: New York, NY, pp. 105-237) can also be used to synthesize the hexapeptides disclosed herein.
[0098] Alternatively, recombinant DNA methods can be used to generate sufficient quantities of hexapeptides, hexapeptide derivatives, or hexapeptide-based molecules for use in the methods of the invention (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 2001; and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, NY, 1994). Such methods generally involve generating nucleic acid (e.g., DNA) encoding the peptide of interest, transferring the nucleic acid molecule encoding the peptide into a suitable vector, and expressing it in large amounts in a cell culture system. DNA coding sequences for hexapeptides or hexapeptide derivatives can be readily prepared synthetically using methods known in the art (see, e.g., MP Edge et al., Nature, 1981, vol. 292:756-762). Suitable recombinant expression vectors include, but are not limited to, plasmid vectors, viral vectors including phage vectors, artificial vectors, yeast vectors, eukaryotic vectors, etc., which contain the necessary genetic elements to direct the expression of the desired coding sequence. Insertion of a nucleic acid molecule into an expression vector results in the coding sequence being operably linked to the necessary regulatory sequences. Expression systems for a variety of hosts are readily available, including the necessary control sequences, such as promoters and polyadenylation signals, and preferably enhancers (see, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, 1989, Cold Spring Harbor Press: Cold Spring, NY; and R. Kaufman, Methods in Enzymology, 1990, vol. 185:537-566). The transformed host cells are then cultured and maintained under conditions favorable for the expression of the desired peptide.The peptides thus produced are recovered and isolated either directly from the culture medium or by lysis of the cells.
[0099] Recombinant techniques may be preferred when the hexapeptide or hexapeptide derivative is linked to a heterologous peptidic moiety, since recombinant techniques are better suited for producing relatively long polypeptides (e.g., more than 10 or 20 amino acids) in large quantities. Thus, as will be appreciated by those skilled in the art, the hexapeptides, or hexapeptide derivatives, or hexapeptide-based molecules described herein can be produced as fusion proteins (i.e., molecules in which the hexapeptide sequence is linked to a fusion partner). The term "fusion partner" refers to an amino acid sequence that confers one or more desirable properties to the fusion protein. Thus, the fusion partner may be an amino acid sequence that improves expression of the hexapeptide, or hexapeptide derivative, or hexapeptide-based molecule in a host cell during preparation of the fusion protein, and / or an amino acid sequence that facilitates purification of the fusion protein, and / or an amino acid sequence that increases the stability of the fusion protein compared to the stability of the non-fused protein (e.g., to obtain a fusion protein with increased stability against proteases), and the like. Examples of suitable fusion partners include, for example, polyhistidine tags, which allow the resulting fusion protein to be easily purified on a nickel chelate column. Glutathione-S-transferase (GST), maltose B-binding protein, or protein A are other examples of suitable fusion partners that can be fused to the hexapeptides described herein using commercially available fusion expression vectors. Fusion partners can also be heterologous peptide moieties as defined above.
[0100] The hexapeptides, their derivatives, and hexapeptide-based molecules according to the present invention can be purified using a variety of standard protein purification techniques, including, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing, and differential solubilization.
[0101] It is recognized that "purity" is a relative term and is not necessarily to be construed as absolute purity, or absolute enrichment, or absolute selection. In some embodiments, the purity of the recovered hexapeptide, hexapeptide derivative, or hexapeptide-based molecule is at least or about 60%, at least or about 70%, at least or about 80%, or at least or about 90% (e.g., at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%), or approximately 100%. In some preferred embodiments, the hexapeptides, hexapeptide derivatives, and hexapeptide-based molecules described herein are preferably recovered in "substantially pure form." As used herein, the term "substantially pure" refers to a purity that allows the inhibitory peptide to be effectively used in its intended application. For human diagnostic and / or therapeutic applications, "substantially pure" preferably refers to being at least or about 97%, at least or about 98%, at least or about 99%, or approximately 100% pure.
[0102] If necessary, the hexapeptide, hexapeptide derivative, or hexapeptide-based molecule may be sterilized after preparation. Sterilization can be accomplished using any of a wide variety of sterilization techniques known in the art, for example, by filtration through a bacterial-retaining filter, by gamma irradiation, by electron beam irradiation, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. Alternatively or additionally, the purified hexapeptide, hexapeptide derivative, or hexapeptide-based molecule may be lyophilized prior to use.
[0103] Hexapeptides, hexapeptide derivatives, and hexapeptide-based molecules can be commercially synthesized by specialized companies such as Proteogenix (Schilligem, France), Genepep (Montpellier, France), Genscript (Piscataway, NJ), New England Peptide (Gardner, MA), and CPC Scientific (Sunnyvale, CA), Peptide Technologies Corp. (Gaithersburg, MD), and Multiple Peptide Systems (San Diego, CA).
[0104] Hexapeptides, hexapeptide derivatives, and hexapeptide-based molecules can be stored under appropriate conditions in either liquid or solid form, as known in the art. For example, peptides should be kept in a cool, dark place after preparation / purification or upon receipt from the supplier. For best storage, they can be stored in a refrigerator at 4° C. or lower, away from bright light. Dried peptides are stable at room temperature for days to weeks, but −20° C. is preferred for long-term storage.
[0105] 4. Combination of inhibitory peptides The inhibitory peptides described herein may be used alone in the method according to the present invention. Alternatively, at least two inhibitory peptides described herein may be used in combination. Thus, in certain embodiments, the combination according to the present invention comprises two inhibitory peptides described herein. In other embodiments, the combination according to the present invention comprises more than two inhibitory peptides described herein, for example, three or four inhibitory peptides.
[0106] In particular, the combination for use in the method according to the invention consists of at least two different inhibitory peptides as described herein, each inhibitory peptide being hexapeptide 3p (SEQ ID NO:5), 4p (SEQ ID NO:6), 4p inv (SEQ ID NO: 18), 5p (SEQ ID NO: 7), 5p inv (SEQ ID NO: 19), 6p (SEQ ID NO: 8), 8p (SEQ ID NO: 9), 8p inv (SEQ ID NO: 21), 9p (SEQ ID NO: 10), 9p inv (SEQ ID NO: 22), 13p (SEQ ID NO: 11), 13p inv (SEQ ID NO: 23), 14p (SEQ ID NO: 12), 14p inv (SEQ ID NO: 24), 23p (SEQ ID NO: 13), 23p inv (SEQ ID NO: 25), 1tp (SEQ ID NO: 14), 1tp inv (SEQ ID NO: 26), 4tp (SEQ ID NO: 15), 4tp inv (SEQ ID NO: 27), 6tp (SEQ ID NO: 16), 6tp inv (SEQ ID NO:28), 0tp inv (SEQ ID NO: 55), and 3tp inv (SEQ ID NO: 56), and any one of their hexapeptide derivatives described herein. In particular, the combination may consist of at least two different inhibitory peptides, each inhibitory peptide being selected from the group consisting of the hexapeptides 3p, 4p, 5p, 6p, 8p, 9p, 13p, 14p, 23p, 1tp, 4tp, 6tp, 0tp, 1p, 2p, ...7p, 8p, 9p, 10p, 11p, 12p, 13p, 14p, 15p, 16p, 17p, 18p, 19p, 20p, 21p, 22p, 23p, 24p, 25p, 26p, 27p, 28p, 29p, 30p, 31p, 32p, 33p, 34p, 35p, 36p, 37p, 38p, 39p, 40p, inv , 1tp inv , and 3tp invor any one of the hexapeptides 4p, 5p, 8p, 9p, 13p, 14p, 23p, 1tp, 4tp, and 6tp, and their hexapeptide derivatives as described herein.
[0107] In certain preferred embodiments, the combination consists of at least two different inhibitory peptides, each inhibitory peptide being one of the hexapeptides 3p, 4p, 4p inv , 5p, 5p inv , 6p, 8p, 8p inv , 9p, 13p, 14p, 14p inv , 23p inv , 1tp, 1tp inv , 4tp, 4tp inv , 6tp inv , 0tp inv , and 3tp inv and inhibitory peptides consisting of or comprising any one of the hexapeptide derivatives thereof described herein.
[0108] In certain preferred embodiments, the combination consists of at least two different inhibitory peptides, each inhibitory peptide being hexapeptide 4p, 4p inv , 5p, 5p inv , 1tp, 1tp inv , 4tp, 4tp inv , 6tp, 6tp inv , 0tp inv , and 3tp inv and any one of the hexapeptide derivatives thereof described herein. In particular, the combination may be comprised of at least two different inhibitory peptides, each of which is selected from the group consisting of the hexapeptides 4p, 5p, 1tp, 4tp, and 6tp, or the hexapeptides 1tp, 4tp, 6tp, 0tp, 1tp, 2tp, 3tp, 4tp, 5tp, 6tp, 7tp, 8tp, 9 ... inv , 1tp inv , and 3tp invand the hexapeptide derivatives thereof described herein.
[0109] In certain embodiments, the relative amounts of the first and second (and third, etc.) inhibitory peptides in a composition are selected to affect the ability of the composition to inhibit one or more individual phenomena observed in pathological tau aggregation (e.g., inhibition of PHF6 self-association, etc.). For example, in the case of a binary combination, the relative amounts may be about 35:65, or about 40:60, or about 45:55, about 50:50, or about 55:45, or about 60:40, or about 65:35.
[0110] II - Use of Inhibitory Hexapeptides and Hexapeptide-Based Molecules As already mentioned above, the hexapeptide sequences provided herein specifically interact (i.e. specifically bind) with the PHF6 peptide, which is essential for the process of nucleation and fibrillation of abnormal tau proteins in the form of paired helical fibrils (PHF) and straight fibrils (SF) found in Alzheimer's disease, and in the form of thin Pick fibrils (NPH) and thick Pick fibrils (WPF) found in Pick's disease. Upon loss of function or deregulation, abnormal tau proteins containing the PHF6 sequence are detached from microtubules and are found free in the cytoplasm, thereby making them accessible to inhibitory peptides. Thus, the inhibitory peptides of the present invention can be used for various applications, including therapeutic and diagnostic applications in the field of tauopathies and disorders associated with abnormal tau aggregation.
[0111] 1 - Inhibition / Therapeutic Applications The present invention relates to the use of the inhibitory peptides described herein in a method for inhibiting the self-association process of PHF6 peptide in vitro, the method comprising the step of contacting the PHF6 peptide, or a sample containing the PHF6 peptide, with an effective amount of the inhibitory peptide under conditions that allow the inhibitory peptide to bind to the PHF6 peptide and inhibit the self-association process of the PHF6 peptide.
[0112] The inhibitory peptide used in the method may be one of the inhibitory peptides described herein or a combination of at least two of the inhibitory peptides described herein. The method is carried out in vitro in a solution, for example, using a model developed by the inventors (see the Examples section). Contacting the PHF6 peptide or a sample thereof with an effective amount of the inhibitory peptide typically includes combining, mixing, or incubating the PHF6 peptide or a sample thereof with the inhibitory peptide. It is within the capabilities of a person skilled in the art to determine the optimal conditions (time, temperature, pH, etc.) that allow the inhibitory peptide to bind to the PHF6 peptide and inhibit the self-association process of the PHF6 peptide.
[0113] Those skilled in the art will recognize that such methods can be used to inhibit the association process of PHF6 peptides in vitro. In this case, the association process is carried out by binding the PHF6 peptide to 374 HKLTF 378 (SEQ ID NO: 3), or with the PHF6 peptide 336 QVEVKS 341 (SEQ ID NO: 4). In such cases, the in vitro models used are the VQIVYK / HKLTF interaction model and the VQIVYK / QVEVKS interaction model, respectively, which are being developed by the present inventors.
[0114] The present invention further relates to the use of the inhibitory peptides described herein in a method for inhibiting, reducing or preventing abnormal tau aggregation, the method comprising the step of contacting an abnormal tau protein, or a biological sample or system containing an abnormal tau protein, with an effective amount of the inhibitory peptide under conditions that allow the inhibitory peptide to bind to a PHF6 sequence present in abnormal tau and inhibit, reduce or prevent abnormal tau aggregation.
[0115] The inhibitory peptide used in such methods may be one of the inhibitory peptides described herein or may be a combination of at least two of the inhibitory peptides described herein. The methods may be performed in vitro (e.g., in cells or other biological systems expressing abnormal tau) or in vivo (in animals, animal models, or patients). Pluripotent stem cells (PSCs), either patient-derived or genome-edited, can aid in the generation of valid and robust in vitro cellular models of tauopathies (Shi et al., Sci. Transl. Med., 2012, 4(124):124ra29; Lovino et al., Brain, 2015, 138(11):334563359; Wray, Brain Pathl., 2017, 27(4):525-529; Arber et al., Alzheimer's Research & Therapy, 2017, 9:42; Garcia-Leon et al., Alzheimers Dement., 2018, 14(10):1261-1280; Karch et al., STEM Cell. Reports, 2019, 13(5):939-955; Lin et al., Pharmaceuticals, 2021, 14(6):525; Penney et al., Molecular Psychiatry, 2020, 25:148-167). Kim and colleagues (Kim et al., Nature Protoc., 2015, 10(7):985-100; Kwak et al., Nature Commun, 2020, 11, 1377, doi.org / 10.1038 / s41467-020-15120-3) have generated a three-dimensional (3D) human neural stem cell model of Alzheimer's disease using the β-amyloid precursor protein and presenilin-1 overexpressing ReNcell™ VM human neural stem cell line. This 3D cell model can induce robust extracellular deposition of amyloid-β, including amyloid-β plaques, as well as high levels of phosphorylated tau in cell bodies and neurites, and fibrillar tau. A 3D neural stem cell model of Alzheimer's disease is also commercially available from Aldrich under the name Alzheimer's In a Dish™.Most of the animal models of tauopathies involve genetically modified animals (mostly rodents, but also fruit flies, zebrafish, and nematodes). For reviews of animal models of tauopathy, see Dujardin et al., Neuropathol. Appl. Neurobiol., 2015, 41(1):59-80; Combs et al., Methods Mol. Biol., 2016, 1382:339-366; Cubinkova et al., Acta Virol., 2017, 61(1):13-21; Gotz et al., Adv. Exp. Med. Biol., 2019, 1184:381-391; Goodarzi et al., Cell Tissue Bank, 2019, 20(2):141-151; et al., Alzheimers Dement. (NY), 2020, 6(1):el2114; Giong et al., Int. J. Mol. Sci., 2021, vol. 22(16):8465. When performed in vivo, the contacting step typically includes administering the inhibitory peptide to an animal, animal model, or patient (see below). When performed in vivo, the method can be used to inhibit the onset or progression of a tauopathy or a disorder associated with abnormal tau aggregation in a subject. Thus, the method can be used to treat or prevent a tauopathy or a disorder associated with abnormal tau aggregation in a subject.
[0116] Thus, the present invention also relates to an inhibitory peptide or combination thereof (optionally after formulation with one or more suitable pharma- ceutically acceptable carriers or excipients) for use in the treatment or prevention of a tauopathy or a disorder associated with abnormal tau aggregation in a subject. The present invention also relates to a method for treating or preventing a tauopathy or a disorder associated with abnormal tau aggregation in a subject, comprising administering a therapeutically effective amount of at least one inhibitory peptide or combination thereof or a pharmaceutical composition thereof to a subject in need thereof. Another aspect of the present invention is a method for treating a subject at an early stage of a disease or condition or a subject developing such a disease or condition, to prevent the onset of a tauopathy or a disorder associated with abnormal tau aggregation in a subject, or to prevent or inhibit the onset of the disease or condition.
[0117] A. Indications In many embodiments, the subject is a human, and more particularly, a patient diagnosed with a tauopathy or a subject determined to be susceptible to developing a tauopathy.
[0118] The tauopathy that can be treated according to the methods described herein can be any neurodegenerative disease involving abnormal aggregation of tau protein into neurofibrillary or gliofibrially tangles in the human brain. Clinically, tauopathies can manifest as cognitive syndromes, movement disorders, motor neuron diseases, or a mixture thereof. Tauopathies that can be treated according to the methods described herein include primary tauopathies and secondary tauopathies. The tauopathies treated can be 3R tauopathies, 4R tauopathies, or mixed 3R / 4R tauopathies. In particular, tauopathies that can be treated using the methods described herein include Alzheimer's disease (AD), Pick's disease (PD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), age-related tau astrogliopathy (ARTAG), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), subacute sclerosing panencephalitis (SSPE), Guadeloupian parkinsonism, Western Pacific amyotrophic lateral sclerosis and parkinsonism-dementia complex (ALS / PDC), chronic traumatic encephalopathy (CTE), Huntington's disease (HD), Niemann-Pick disease type C (NPC), Down's syndrome, postencephalitic parkinsonism (PEP), and myotonic dystrophy (types 1 and 2).
[0119] In certain embodiments, the tauopathy to be treated using the methods of the present invention is selected from the group consisting of Alzheimer's disease, Pick's disease, progressive supranuclear palsy (PSP), and argyrophilic grain disease (AGD). Alzheimer's disease, the most prevalent tauopathy, is a progressive disease that begins with mild memory loss and can lead to loss of ability to carry on a conversation and respond to the environment, severely affecting an individual's ability to carry out daily activities. Pick's disease (or frontotemporal dementia (FTD)) is a rare type of dementia that affects the frontal lobes of the brain, causing language disorders such as aphasia, behavioral disorders, and ultimately death. Pick's disease is the second most prevalent after Alzheimer's disease, accounting for 20% of early-onset dementia cases. Although it can occur in people as young as 20 years old, it usually begins between the ages of 45 and 65, and men and women are affected almost equally. Progressive supranuclear palsy (PSP) is a late-onset degenerative disease that involves the gradual deterioration and death of certain parts of the brain. The condition is associated with symptoms including loss of balance, bradykinesia, eye movement difficulties, and cognitive impairment. PSP affects approximately 6 per 100,000 individuals, with the first symptoms typically appearing in individuals aged 60-70 years, with men being slightly more likely to be affected than women. Argyrophilic grain disease (AGD) is a common, yet still under-recognized, neurodegenerative condition. AGD has been found to be the second most common neurodegenerative disease after Alzheimer's disease. The incidence of AGD increases significantly with age, with its prevalence estimated to range from 9.3% in individuals aged 65 years to 31.3% in centenarians. AGD is clinically characterized by amnesia and prominent neuropsychiatric features with relative preservation of other cognitive functions.
[0120] The effectiveness of treatment according to the invention can be monitored using any of the assays known in the art for diagnosing the disease being treated. Alternatively or additionally, the effectiveness of treatment according to the invention can be monitored using the diagnostic methods described herein (see below).
[0121] B. Administration The inhibitory peptide or combinations thereof (optionally after formulation with one or more suitable pharma- ceutically acceptable carriers or excipients) can be administered in a desired dosage to a subject in need thereof by any suitable route. A variety of delivery systems are known and can be used to administer the inhibitory peptides of the present invention, including tablets, capsules, injectable solutions, liposomal encapsulation, microparticles, microcapsules, and the like. Methods of administration include, but are not limited to, transdermal, intradermal, intramuscular, intraperitoneal, intralesional, intravenous, subcutaneous, intranasal, pulmonary, epidural, ocular, and oral routes. The inhibitory peptide or compositions thereof can be administered by any convenient or other suitable route, for example, by infusion or bolus injection, by adsorption through epithelial or mucocutaneous linings (e.g., oral, mucosal, rectal, and intestinal mucosa, etc.). Administration can be systemic or local. In particular, administration can be by injection into the CSF (cerebrospinal fluid) route or by direct injection into the brain. Parenteral administration can be directed to a given tissue of a patient by catheterization, etc. As will be appreciated by one of skill in the art, in embodiments in which an inhibitory peptide or composition thereof is administered with an additional therapeutic agent, the inhibitory peptide and the therapeutic agent may be administered by the same route (e.g., orally) or by different routes (e.g., orally and intravenously).
[0122] The inhibitory peptides or combinations thereof may be administered by incorporation into a catheter, needle, or implant (optionally after formulation with one or more appropriate pharma- ceutically acceptable carriers or excipients).
[0123] C. Dosage Administration of the inhibitory peptide or combination thereof (optionally after formulation with one or more suitable pharma- ceutically acceptable) will be at a dosage such that the delivered amount is effective for the intended purpose. The route of administration, formulation, and dosage administered will depend on the desired therapeutic effect, the severity of the disease being treated, the age, sex, weight, and general health of the patient, as well as the potency, bioavailability, and in vivo half-life of the inhibitory peptide or combination thereof used, the use (or not) of concomitant therapy, and other clinical factors. Such factors can be readily determined by the attending physician during the course of therapy. Alternatively or additionally, the dosage to be administered can be determined from studies using animal models. Adjusting the dose to achieve maximum efficacy based on these or other methods is well known in the art and within the capabilities of a trained physician. As studies using the inhibitory peptides of the present invention are conducted, more information regarding appropriate dosage levels and duration of treatment will become clear.
[0124] Treatment according to the present invention may consist of a single dose or multiple doses. Thus, administration of the inhibitory peptide or pharmaceutical composition thereof may be constant over a period of time, or may be periodic and at specific intervals, for example, hourly, daily, weekly (or at any other multiple day interval), monthly, yearly (e.g., in sustained release form). Alternatively, delivery may occur multiple times during a given period of time, for example, twice or more weekly, twice or more monthly, etc. Administration may be continuous administration over a period of time, for example, intravenous delivery.
[0125] Generally, however, a suitable dose will be in the range of about 0.001 to about 100 mg / kg of recipient body weight per day, such as about 0.01 to about 100 mg / kg of body weight per day, for example, greater than about 0.1 mg / kg of body weight per day, or in the range of about 1 to about 10 mg / kg of body weight per day. For example, a suitable dose may be about 1 mg / kg of body weight, 5 mg / kg of body weight, 10 mg / kg of body weight, 20 mg / kg of body weight, or 30 mg / kg of body weight per day.
[0126] The inhibitory peptides of the present invention can be conveniently administered in unit dosage forms, e.g., containing 0.05-10,000 mg, 0.5-10,000 mg, 5-1,000 mg, or about 100 mg of active ingredient per unit dosage form, hi some embodiments, dosage units contain about 0.1 mg, about 0.5 mg, about 1 mg, about 10 mg, about 25 mg, about 50 mg, about 75 mg, or about 100 mg of active ingredient.
[0127] D. Combination Therapy Treatment according to the invention can be administered alone or in combination with other therapies (i.e., therapeutic agents and / or therapeutic procedures), particularly those known to be beneficial to patients suffering from tauopathies. The inhibitory peptides or combinations thereof (optionally after formulation with one or more suitable pharma- ceutically acceptable carriers or excipients) can be administered prior to, simultaneously with, and / or after administration of the additional therapeutic agent or procedure.
[0128] Treatment of tau-related neurodegenerative syndromes is limited and mainly symptomatic. Currently, there are two types of drugs approved for cognitive function: cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, each of which has shown moderate effectiveness. Motor symptoms may respond to dopamine regimens, speech therapy has shown some effectiveness in aphasia syndromes (acquired language dysfunction due to neurological damage or disease), and physical therapy has been found to help extend motor function. Symptoms of blunted affect and depression are very common and often respond to therapy or pharmacological interventions, including selective serotonin reuptake inhibitors. Thus, the inhibitory peptide or combination thereof or pharmaceutical composition thereof can be administered in combination with at least one additional therapeutic agent or therapeutic procedure selected from cholinesterase inhibitors, N-methyl-D-aspartate (NMDA) receptor antagonists, dopamine regimens, selective serotonin reuptake inhibitors, speech therapy, physical therapy, and any beneficial combination thereof.
[0129] 2 - Diagnostic Applications The inhibitory peptides described herein specifically interact with the PHF6 sequence present in tau protein and can be used to detect abnormal or pathological tau, i.e., tau that is found free in the cytoplasm of neurons due to loss of function or deregulation. In certain preferred embodiments, the inhibitory peptide comprises a detectable moiety.
[0130] Thus, the present invention relates to an in vitro method for detecting the presence or absence of abnormal tau protein in a biological sample, comprising contacting the biological sample with an effective amount of an inhibitory peptide, preferably but not necessarily labeled with a detectable moiety, under conditions that allow the inhibitory peptide to bind to abnormal tau protein, and detecting the presence or absence of the inhibitory peptide bound to the abnormal tau protein in the biological sample. The method can be performed on a biological sample (e.g., a sample of cerebrospinal fluid) obtained from an individual suspected of suffering from a tauopathy. Such a method can be used, for example, in diagnostic strategies designed to monitor the presence or status of a tauopathy (e.g., Alzheimer's disease or Pick's disease), for example, to detect disease onset before clinical symptoms, and / or to follow the effectiveness (or lack of effectiveness) of a therapeutic treatment.
[0131] The present invention also relates to an inhibitory peptide or a composition thereof for use in diagnosing a tauopathy or a disorder associated with abnormal tau aggregation in a subject. The present invention also relates to a method for diagnosing a tauopathy or a disorder associated with abnormal tau aggregation in a subject, comprising administering to the subject a diagnostically effective amount of an inhibitory peptide or a composition thereof and detecting any inhibitory peptide bound to abnormal tau protein, wherein detection of inhibitory peptide bound to abnormal tau protein indicates that the subject suffers from or is at risk of developing a tauopathy or a disorder associated with abnormal tau aggregation. In particular, the method can be used for early diagnosis of a tauopathy or a disease associated with abnormal tau aggregation. Alternatively or additionally, the method can be used to select a therapy that is particularly suitable for the patient being tested.
[0132] Administration of a diagnostically effective amount of an inhibitory peptide or a composition thereof to a subject can be performed using any suitable administration method known in the art (see above). However, in certain embodiments, administration is preferably performed by injection of a composition, such as an aqueous composition, comprising the labeled inhibitory peptide. The dose of the labeled inhibitory peptide will vary depending on the type of compound to be administered, the weight of the patient, and other variables that would be apparent to a skilled physician. In general, the dose will preferably be in the range of 0.001 μg / kg to 10 μg / kg, preferably 0.01 μg / kg to 1.0 μg / kg. When the inhibitory peptide used in the diagnostic method is labeled with a radioactive moiety, the radioactive dose may be such that about 1 μCi to about 10 mCi / kg body weight, or about 5 μCi to about 1 mCi / kg body weight, or about 10 μCi to about 100 μCi / kg body weight, or about 1 mCi to about 10 mCi / kg body weight is administered at one time. The radioactive dose may be, for example, 100 to 600 MBq, more preferably 150 to 450 MBq.
[0133] As is known in the art, after administration but prior to the detection step, the labeled inhibitory peptide is allowed to distribute to the tissue of interest (here brain tissue) and bind to any free abnormal tau protein present. The time required for tissue distribution and binding will depend on the labeled inhibitory peptide and can be determined by one of ordinary skill in the art by routine experimentation.
[0134] As will be understood by those skilled in the art, the inhibitory peptide labeled with detectable moiety will be selected based on the detection technique intended to be used for diagnosis.Preferably, detection is performed using imaging techniques, and the diagnostic method comprises imaging at least a part of the subject's brain to detect any inhibitory peptides bound to abnormal tau protein.The most widely used neuroimaging methods are magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and single photon emission computed tomography (SPECT).In a particular preferred embodiment, imaging is performed using PET.
[0135] In other embodiments, multimodal or multiplex imaging is used in the detection step. Multimodal or multiplex imaging refers to the simultaneous generation of signals from more than one imaging technique. The first main reason is that there is a large complementarity between different imaging modes. For example, images obtained by positron emission tomography (PET) or single photon emission computed tomography (SPECT) do not contain high-resolution three-dimensional anatomical information. On the other hand, high-resolution structural images can be obtained by using CT and / or MRI. These images complement each other to provide a complete picture of the anatomical, physiological and pathological characteristics of the target organ. Thus, in certain embodiments, the detection or imaging step is performed by a multimodal imaging technique, including MRI-based imaging and PET-based imaging.
[0136] Imaging techniques can provide quantitative data. Thus, the amount or level of the labeled inhibitory peptide bound to abnormal tau detected in the subject's brain or a part of the brain can be compared with a normal control amount or level determined in the brain or the same part of the brain of a healthy subject (i.e., a subject not suffering from a tauopathy or a disorder associated with abnormal tau aggregation), or with a normal control amount or level that is the average of the determinations performed in several healthy subjects (e.g., 5, 10, 20, 50, 100, 500, or more than 500 people). If the amount or level of the labeled inhibitory peptide bound to abnormal tau detected in the subject's brain or a part of the brain is higher than the normal control amount or level, it indicates that the subject suffers from or is at risk of developing a tauopathy or a disorder associated with abnormal tau aggregation. The amount or level of labeled inhibitory peptide bound to abnormal tau detected in the subject's brain or part of the brain can be further compared to one or more pre-defined thresholds corresponding to different diagnoses (early tauopathy, various stages of tauopathy, specific tauopathy, etc.).
[0137] Using the diagnostic methods described herein, a skilled physician can select and prescribe an appropriate treatment for each patient based on the diagnosis reached. The selection of an appropriate therapeutic regimen for a given patient can be made solely on the basis of the diagnosis provided by the diagnostic methods disclosed herein. Alternatively, the physician can also take into account other clinical or pathological parameters used in existing methods for diagnosing tauopathies.
[0138] The diagnostic methods described herein can be used to monitor the effectiveness of tauopathy treatment in patients. In such methods, the amount or level of labeled inhibitory peptide bound to abnormal tau may be detected at various times during treatment, for example, before and after treatment is started, or at various times after treatment is started. A decrease in the amount or level of labeled inhibitory peptide bound to abnormal tau indicates that the tauopathy treatment is effective in the patient, or in other words, that the patient is responsive to the tauopathy treatment.
[0139] III - Pharmaceutical compositions and packs and diagnostic kits 1 - Pharmaceutical Compositions As mentioned above, in therapeutic and / or diagnostic applications, the inhibitory peptides described herein can be administered per se or as a pharmaceutical composition. Accordingly, the present invention provides pharmaceutical compositions comprising an effective amount of at least one inhibitory peptide and at least one pharma- ceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition further comprises one or more additional biologically active agents.
[0140] The pharmaceutical composition of the present invention can be formulated in dosage unit form for ease of administration and uniformity of dosage.The expression "unit dosage form" as used herein refers to a physically separate unit of at least one inhibitory peptide for the patient to be treated / subject to be tested.However, it will be understood that the total daily dosage of the composition will be determined by the attending physician within the scope of sound medical judgment.
[0141] A. Formulations The pharmaceutical compositions described herein can be administered using any amount and any route of administration effective to achieve the desired prophylactic and / or therapeutic effect and / or diagnostic purpose. Optimal pharmaceutical formulations may vary depending on the route of administration (oral, nasal, intraperitoneal, or parenteral, intravenous, intramuscular, topical, subcutaneous, or by injection into tissue) and the desired dosage. Such formulations can affect the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the administered active ingredient.
[0142] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations can also be sterile injectable solutions, suspensions, or emulsions in non-toxic parenterally acceptable diluents or solvents, for example, as a solution in 2,3-butanediol. Vehicles and solvents that can be used include water, Ringer's solution, USP, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as a solution or suspension medium. For this purpose, any non-irritating fixed oil can be used, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid, can also be used to prepare injectable preparations. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration.
[0143] Injectable preparations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium before use. Liquid pharmaceutical compositions that are sterile solutions or suspensions can be administered, for example, by intravenous, intramuscular, intraperitoneal, or subcutaneous injection. Injection can be by a single push or by slow infusion. If necessary or desired, the composition can include a local anesthetic to ease pain at the site of the injection.
[0144] In order to prolong the effect of an active ingredient, it is often desirable to slow the absorption of the ingredient from subcutaneous or intramuscular injection. Delayed absorption of parenterally administered active ingredients can be accomplished by dissolving or suspending the ingredient in an oil vehicle. Injectable depot forms are prepared by forming microencapsulated matrices of the active ingredient in biodegradable polymers, such as polylactide polyglycolide. Depending on the ratio of active ingredient to polymer and the nature of the particular polymer used, the rate of ingredient release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations can also be prepared by entrapping the active ingredient in liposomes or microemulsions that are compatible with body tissues.
[0145] Liquid dosage forms for oral administration include, but are not limited to, pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, elixirs, and pressurized compositions. In addition to at least one inhibitory peptide, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof. In addition to the inert diluent, the oral composition may also contain auxiliary agents such as wetting agents, suspending agents, preservatives, sweeteners, flavorings, and aromatics, thickeners, coloring agents, viscosity regulators, stabilizers, or osmotic pressure regulators. Examples of liquid carriers suitable for oral administration include water (which may contain additives such as those described above, such as cellulose derivatives, e.g., sodium carboxymethylcellulose solution), alcohols (including monohydric and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and peanut oil). For pressurized compositions, the liquid carrier may be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.
[0146] Solid dosage forms for oral administration include, for example, lozenges, troches, tablets, capsules, effervescent tablets, orally disintegrating tablets, floating tablets designed to increase gastric residence time, buccal patches, and sublingual tablets. In such solid dosage forms, the inhibitory peptide or combinations thereof may be mixed with at least one inert pharma- ceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and one or more of the following: (a) a filler or extender, such as starch, lactose, sucrose, glucose, mannital, and silicic acid; (b) a binder, such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) a humectant, such as glycerol; (d) disintegrants such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (e) dissolution retardants such as paraffin; absorption promoters such as quaternary ammonium compounds; (g) wetting agents such as cetyl alcohol and glycerol monostearate; (h) absorbents such as kaolin and bentonite clay; and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. Other excipients suitable for solid formulations include surface modifiers, such as nonionic and anionic surface modifiers. Representative examples of surface modifiers include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecyl sulfate, magnesium aluminum silicate, and triethanolamine. In the case of capsules, tablets and pills, the dosage form may further comprise buffering agents.
[0147] Solid compositions of a similar type can also be used as fillers for soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar as well as high molecular weight polyethylene glycols, etc. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulating art. Examples of embedding compositions that can be used include polymeric substances and waxes.
[0148] In certain embodiments, it may be desirable to administer the compositions of the invention locally, which can be accomplished, for example and without limitation, by local infusion during surgery, injection, topical application via a catheter, suppository, or by a skin patch, stent, or other implant.
[0149] For topical administration, the composition is preferably formulated as a gel, ointment, lotion, or cream that may contain a carrier such as water, glycerol, alcohol, propylene glycol, fatty alcohol, triglyceride, fatty acid ester, or mineral oil. Other topical carriers include liquid petroleum, isopropyl palmitate, polyethylene glycol, ethanol (95%), polyoxyethylenemonolaurat (5%) in water, or sodium lauryl sulfate (5%) in water. Other substances such as antioxidants, humectants, viscosity stabilizers, and similar agents may be added as needed.
[0150] In addition, it is expected that in certain cases, the composition of the present invention may be placed in a transdermal device that is located on, in, or under the skin. Such devices include patches, implants, and injections that release active ingredients by either passive or active release mechanisms. Transdermal administration includes all administrations through the surface of the body and the inner lining of body passages, including epithelial and mucosal tissues. Such administrations can be carried out using the composition of the present invention in the form of lotions, creams, foams, patches, suspensions, solutions, sprays, and suppositories (rectal and vaginal).
[0151] Transdermal administration can be accomplished by the use of a transdermal patch containing the active ingredient (i.e., the inhibitory peptide) and a carrier that is non-toxic to the skin and allows the ingredient to be delivered through the skin into the bloodstream for systemic absorption. The carrier can take any number of forms, such as creams and ointments, pastes, gels, and occlusive devices. Creams and ointments can be viscous liquids or semisolid emulsions, either oil-in-water or water-in-oil. Pastes consisting of absorbent powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may be suitable. A variety of occlusive devices, semipermeable membranes covering a reservoir containing the active ingredient with or without a carrier, or matrices containing the active ingredient can be used to release the active ingredient into the bloodstream.
[0152] Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of various molecular weights, can also be used.
[0153] For administration by intranasal delivery (e.g., nasal mucosal delivery for intranasal mucosal delivery) via inhalation or insufflation, at least one inhibitory peptide described herein can be combined with a fine inert powder carrier or liquid carrier. One or more mucosal delivery enhancers may also be present. Examples of absorption enhancers for intranasal adsorption of peptide drugs include, but are not limited to, bile salts, surfactants, fluidic acid derivatives, phosphatidylcholines, cyclodextrins, and cell penetrating peptides (CPPs).
[0154] Materials and methods for producing the various formulations are known in the art and can be applied to practice the subject invention. Formulations suitable for delivery of antibodies can be found, for example, in "Remington's Pharmaceutical Sciences", EW Martin, 18th Edition, 1990, Mack Publishing Co.: Easton, Pa.
[0155] B. Additional Biologically Active Agents In certain embodiments, the inhibitory peptides described herein are the only active ingredient in the pharmaceutical composition of the present invention. In other embodiments, the pharmaceutical composition further comprises one or more biologically active agents. Examples of suitable biologically active agents include, but are not limited to, anti-inflammatory agents, immunomodulatory agents, analgesics, antimicrobial agents, antibacterial agents, antibiotics, antioxidants, preservatives, and combinations thereof.
[0156] In such pharmaceutical compositions, the inhibitory peptide and at least one additional therapeutic agent may be combined in one or more preparations for simultaneous, separate or sequential administration of the peptide and the therapeutic agent. More specifically, the compositions of the present invention may be formulated so that the inhibitory peptide and the therapeutic agent can be administered together or independently of each other. For example, the inhibitory peptide and the therapeutic agent may be formulated together in a single pharmaceutical composition. Alternatively, they may be maintained (e.g., in different compositions and / or containers) and administered separately, thereby constituting a pharmaceutical kit or pack.
[0157] 2 - Medicine packs and diagnostic kits In another aspect, the present invention provides a pharmaceutical pack or kit comprising one or more containers (e.g., vials, ampoules, test tubes, flasks, or bottles) containing one or more of the ingredients of the pharmaceutical compositions of the invention, allowing for the administration of at least one inhibitory peptide described herein for therapeutic and / or diagnostic purposes to a subject in need thereof.
[0158] The various components of the pharmaceutical pack or kit may be supplied in solid (e.g. lyophilized) or liquid form. Each component will generally be suitably provided in its respective container in a portioned or concentrated form. The pack or kit according to the invention may also include a medium for reconstituting the lyophilized components. The individual containers of the kit will preferably be maintained in hermetically sealed condition for commercial sale.
[0159] In certain embodiments, the pharmaceutical pack or diagnostic kit can include a device for administering the inhibitory peptide or a composition thereof, such as a needle, a pen device, a jet injector, or another needle-free injector.
[0160] In certain embodiments, the pharmaceutical pack or diagnostic kit includes one or more additional therapeutic agents. Optionally, the container may be accompanied by a notice or package insert in a form prescribed by a government regulatory agency regulating the manufacture, use, or sale of pharmaceutical or biological products, the notice reflecting approval by the regulatory agency of the manufacture, use, or sale for human administration. The notice on the package insert may include instructions for using the pharmaceutical composition in accordance with the treatment method disclosed herein. Alternatively or additionally, the package insert may include instructions for using the diagnostic kit in accordance with the diagnostic method disclosed herein. The instructions for using the kit in accordance with the diagnostic method may include instructions for preparing the patient for administration and / or imaging, and / or instructions for performing the imaging portion of the diagnostic method, and / or instructions for interpreting the results obtained. The kit may also include a software package that allows for statistical analysis with necessary corrections and normalizations.
[0161] Optionally, the container may be accompanied by a notice or package insert in a form prescribed by a government regulatory agency regulating the manufacture, use, or sale of the pharmaceutical or biological product, the notice reflecting approval by the regulatory agency of the manufacture, use, or sale for human administration.
[0162] An identifier may be present in or on the kit, e.g., a bar code, radio frequency, ID tag, etc. The identifier may be used, for example, to uniquely identify the kit for purposes of quality control, inventory control, tracking movement between work sites, etc.
[0163] The present invention will be further illustrated by the following figures and examples, which, however, should not be construed in any way as limiting the scope of the present invention. EXAMPLES
[0164] Working Example The following examples describe some of the preferred modes for making and practicing the present invention. However, it should be understood that the examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, unless the description of the examples is set forth in the past tense, the text, as well as the remainder of the specification, is not meant to imply that the experiments were actually performed or the data actually obtained.
[0165] Example 1 Identification of a hexapeptide that efficiently targets PHF6 interactions Two problems remain regarding the management of Alzheimer's disease and other tauopathies. First, diagnosis is difficult and often not confirmed until postmortem. Second, there is still no treatment that can halt or even slow down the pathological progression. This work provides a new molecule that allows a dual diagnostic and therapeutic approach (theragnostics). More specifically, the goal is to generate a molecule with a single tool that can be used (i) as a therapeutic agent to treat tauopathies and (ii) as a probe for the early diagnosis of tauopathies. The backbone of such a molecule is a synthetic hexapeptide that inhibits the intramolecular interactions involved in the formation of amyloid structures within abnormal tau proteins. More precisely, the identified hexapeptide is the PHF6 peptide ( 306 VQIVYK 311 , SEQ ID NO: 2) and itself, and 374 HKLTF 378 (SEQ ID NO: 3), and the interaction of the PHF6 peptide with itself and 336 QVEVKS 341 (SEQ ID NO: 4). These interactions, which are responsible for the nucleation process of amyloid aggregation, occur through two separate or simultaneous nucleation steps: β1-β1 and β1-β8 in Alzheimer's disease, and β1-β1 and β1-β4 in Pick's disease (see FIG. 1).
[0166] I. Selection of synthetic hexapeptides derived from VQIVYK (SEQ ID NO:2) A. Hexapeptides studied 1. The first 22 hexapeptides In a previous study aimed at providing answers regarding the laws governing amyloid aggregation (paper "Chaperons moleculaires et tauophathies: Effectet de Hsp90 on the fibrillation in vitro of the peptide VQIVYK issu de la proteine tau", Claire Schirmer, 2014, Universite de Rennes, France), our research group carried out a comparative study of the amyloidogenicity of permutation variants derived from the VQIVYK peptide. The replacement of each of the six amino acids (two valine residues, one glutamine, one isoleucine, one tyrosine, one lysine) leads to 360 possible combinations. Of these 360 combinations, only 93 are actually found in proteins. Interestingly, all 360 variants have an aggregation score between 67.592 and 93.416. These scores are particularly high: out of 64 million possible hexapeptides, only 219387 (0.34%) have a score higher than or equal to 67.592. Twenty-two sequences were selected based on their "MetAmyl" score compared to the reference peptide VQIVYK, derived from the tau protein, which has a score of 67,671 (Table 2).
[0167] [Table 2]
[0168] 2. 10 additional hexapeptides As described previously, VQIVYK (peptide 1p) is an essential segment for the formation of amyloid fibrils of the whole tau protein. In addition, it is a good model for the study of the assembly process in vitro, where the structure formed is a parallel β-sheet that interacts "face-to-face" and "back-to-up" through its side chains. To compete with the "face-to-face" interaction, potential inhibitory peptides should have at least a glutamine-valine-lysine (QVK) or valine-isoleucine-tyrosine (VIY) sequence on either side of the peptidic chain, in the same position as VQIVYK. None of the 22 peptides described above and previously studied exhibit such a sequence. Therefore, 10 additional hexapeptides (see Table 3) were designed and generated. These 10 hexapeptides were designed to be able to compete with the "face-to-face" interaction observed in VQIVYK. V Q I V Y Three even or odd amino acids at the same position as K (i.e. V - I - Y , or QVK).
[0169] [Table 3]
[0170] These 10 peptides were studied, as were the previous 22 peptides, by both bioinformatics and biochemical techniques.
[0171] B. Materials and Methods 1. Solubilization of peptides The PHF6 peptide (Ac-VQIVYK-NH2) as well as derived hexapeptides were produced in N-acetylated and C-amidated form by Proteogenix® and supplied in lyophilized form. They are acetylated and amidated to better mimic the original protein. They were resuspended in Milli-Q water and filtered at 0.2 μm to obtain a concentration close to 5 mg / mL. After vortexing for 15 min, the peptide solution was sonicated in an ultrasonic water bath (Advantage-Lab AL04-04) for 15 min at 35°C and then ultracentrifuged (Beckman TL100) at 100,000g for 10 min at 20°C. The pellet containing residual aggregates was discarded. The concentration of the supernatant was determined by the molar extinction coefficient of 1450 M -1 cm -1 The concentration was determined by measuring the UV absorption at 280 nm in 1% SDS using
[0172] 2. Peptide Polymerization After thawing, a pre-dilution with 0.2 μm filtered Milli-Q H2O was performed to obtain a solution with a concentration of >1.25x, close to the working concentration. This stock solution was incubated statically in a 25°C water bath for 1 h, then assayed spectrophotometrically and adjusted to 1.25x the final working concentration. Polymerization was initiated by adding ¼ of the volume of 5x fibrillation buffer (50 mM MOPS, 750 mM NaCl, pH=7.2) to a final concentration of 1x fibrillation buffer (10 mM MOPS, 150 mM NaCl, PH=7.2). Samples were incubated statically in a water bath for 1.5-2 h at 25°C. Fluorescence polymerization studies were performed under the same conditions, except that the 5x polymerization buffer was supplemented with 100 μM Thioflavin T (ThT) so that fluorescence could be observed.
[0173] (a) Determination of the aggregation properties of the peptides. After polymerization, the samples were ultracentrifuged at 100,000 g for 5 min at 25° C. (Beckman TL100, rotor TL-A100). The supernatant of each sample was then collected. The assay of each supernatant in triplicate was then carried out at 280 nm in the presence of 1% SDS. The Beer-Lambert law A=ε×l×C; ε(peptide)=1450M -1 cm -1 The concentration of the supernatant was determined using the ELISA kit. The concentration of the sedimentable species in the pellet was then estimated by the difference: "total concentration of the sample - concentration of the free peptide present in the supernatant".
[0174] (b) Determination of the amyloidogenic properties of the peptides. Once the peptides were polymerized as previously shown, 40 μL of polymerized peptides at concentrations of 400 μM and 800 μM were diluted with 360 μL of Thioflavin T (10 μM ThT, 1×MOPS) in a 0.2×1 cm thermostatically controlled tank to a final volume of 400 μL. The fluorescence of the samples was then measured (Perkin Elmer LS 55, PM 750, slit10) by recording the fluorescence spectra (470 nm to 600 nm) at an excitation wavelength of 450 nm immediately after dilution.
[0175] 4. Bioinformatics prediction of amyloidogenic properties of peptides. The prediction of amyloidogenicity of peptides was performed using a hypothetical sequence consisting of various peptides linked together and separated by a "spacer" peptide flanked by two glycine residues, which are known to have zero aggregation properties. G PNSKQSQDE G(SEQ ID NO: 51). Four independent prediction methods (Aggrescan, Pasta 2.0, Tango, and Salsa) were used, as described by Gamier et al. (Sci. Rep., 2017, 7:6812). The results obtained with the Aggrescan and Salsa prediction methods were found to be indistinguishable, so these two methods were not taken into account and only the Tango and Pasta 2.0 methods were used. The amino acid with the highest probability in each of these two methods was assigned a score of 100%. Each amino acid was assigned the average of the percentages obtained using the two different methods. The score of each peptide is the average of the scores of each amino acid that composes it. All scores of each peptide were normalized by considering the score of the reference peptide VQIVYK(1p) as 100%.
[0176] C. Results 1. Bioinformatics methods The results obtained are shown in Figure 2. The amyloidogenicity score of 1p was set to 100% and the scores of the other peptides were normalized to 1p. In the set of 22 peptides (red in Figure 2), the percentage of amyloidogenicity calculated in this way was found to vary from 3 for the 6p peptide to 160 for the 13p peptide. The 22 hexapeptides can be classified into three categories: those predicted to be strongly amyloidogenic (1p, 12p, 13p, and 17p), those predicted to be weakly amyloidogenic (3p, 4p, 5p, 6p, 9p, 21p, 22p, and 23p), and peptides in between. In the set of 10 additional peptides (green in Figure 2), the percentage of amyloidogenicity was found to vary from 9 for the 0tp peptide to 100 for the 2tp peptide. The ten hexapeptides can be divided into two categories: those predicted to be strongly amyloidogenic (1tp, 2tp, 3tp, 5tp, 6tp, 7tp, 8tp, and 9tp) and those predicted to be weakly amyloidogenic (0tp, 4tp, and 10tp). Being chains of amino acids, the ten additional hexapeptides in this batch are primarily amyloidogenic.
[0177] 2. Biochemical methods After bioinformatics predicted the amyloidogenic properties, all peptides were studied using biochemical methods, namely precipitation and fluorescence / ThT. Biochemical experiments were performed at two peptide concentrations: 400 μM and 800 μM. Only the results obtained at 800 μM are shown. For precipitation at this concentration, the amount of precipitable peptide after polymerization was measured and expressed as a percentage as a function of the total concentration. This value corresponds to the aggregation properties of the peptides. On the other hand, a fluorescence test was used to determine the amyloidogenic properties. The obtained fluorescence values correspond to normalization to 1p, whose fluorescence was considered to be 100% (Table 4).
[0178] [Table 4]
[0179] All biochemical results indicate that these peptides exhibit a large heterogeneity in terms of both aggregation and amyloidogenic properties, as observed in the bioinformatics predictions. In the set of the first 22 hexapeptides, the percentage of precipitating peptides varies from 0 (8p, 13p) to about 95 (1p, 17p). All peptides studied show a lower fluorescence than that of 1p. Some show significant fluorescence (82% and 25% for 12p and 11p, respectively). However, most of these show a very weak fluorescence compared to 1p. In the set of 10 additional hexapeptides, the percentage of precipitating peptides varies from 0 (0tp, 1tp, and 4tp) to about 85 (7tp). The 7tp hexapeptide shows a much higher percentage of fluorescence than 1p (×4.5). The other peptides show significant fluorescence reflecting their amyloidogenic nature, with 5tp and 8tp at about 70% and about 20%, respectively. The other peptides show very low fluorescence compared to 1p.
[0180] To compare the two biochemical parameters studied, the results obtained are presented in the form of a Gamier-Delamarche graphical representation (Figure 3). In this representation, each peptide is represented as a dot whose coordinates reflect both its amyloidogenic and its aggregation properties. The 1p peptide is located at the top left of the graph, reflecting its strong amyloidogenic and autoaggregation potential. Of the 22 initial peptides, some peptides are amyloidogenic and poorly aggregating (21p) and vice versa (19p). In the set of 10 additional hexapeptides, some are amyloidogenic and aggregating (5tp, 7tp) and others are weakly amyloidogenic and weakly aggregating (1tp, 4tp, and 6tp).
[0181] Of the 32 hexapeptides studied, 10 were selected for further investigation: 4p, 5p, 6p, 9p, 13p, 14p, 23p, 1tp, 4tp, and 6tp, which are weakly amyloidogenic and weakly aggregated.
[0182] II. Effects of 10 selected synthetic hexapeptides on PHF6 polymerization First, a research model that allowed observing and characterizing the polymerization kinetics of amyloid fibrils formed in vitro by VQIVYK (PHF6) was reapplied and optimized. Then, ten selected hexapeptides derived from VQIVYK (4p, 5p, 6p, 9p, 13p, 14p, 23p, 1tp, 4tp, and 6tp) were tested for their effect on VQIVYK aggregation.
[0183] A. Materials and Methods 1. Solubilization of the peptide. See above. 2. Preparation of 5x fibrillation buffer For a 100 mL solution of 5x fibrillation buffer (50 mM MOPS, 750 nM NaCl, pH 7.2), 10 mL of 500 mM MOPS and 25 mL of 3 M NaCl were supplemented with sterile water. The pH was adjusted to 7.2 with sodium hydroxide.
[0184] 3. Peptide Polymerization After thawing, a pre-dilution of the peptide of interest with sterile water was performed for each peptide to obtain a solution with a concentration close to the working concentration. The peptides were then incubated overnight at 4°C. On the day of the experiment, the peptide solutions were sonicated for 10 min, left at room temperature for 1 h, sonicated again for 10 min, and then analyzed by NMR spectroscopy at 280 nm (ε = 1450 M). -1 cm -1 ) for 1 h. UV spectra were pre-normalized to 0 at 300 nm. Solutions were prepared to peptide concentrations greater than ¼ of the final desired concentration. Polymerization of VQIVYK was initiated by adding ¼ of the volume of 5× fibrillation buffer to a final concentration of 1× fibrillation buffer (10 mM MOPS, 150 mM NaCl, PH=7.2).
[0185] 4. Critical Assembly Concentration (CCa) Polymerization of VQIVYK was initiated by mixing VQIVYK peptide (various concentrations, 52 μM to 344 μM) with ¼ of its volume of 5× fibrillation buffer. After polymerization, samples were sedimented at 16,900 g for 15 min. The concentration of free peptide was measured by assaying with a nanodrop800. Thus, the concentration of polymerized peptide was determined using the following relationship: [1p] ペレット =[lp] 初期 -[lp] 上清
[0186] 5. Effect of derived peptides on VQIVYK polymerization by fluorescence spectroscopy The analysis was carried out on a fluorescence spectrometer (Perkin Elmer LS55) equipped with a 4-cell rack. Black quartz cells (0.2 × 1.0 cm) were used. The excitation and emission wavelengths were 450 nm and 480 nm, respectively, and the sensitivity (photomultiplier tube "PM") was set at 800 V. The slit size varied from 3 nm to 6 nm. Normalization of each kinetic was performed with respect to the position of the cell in the rack.
[0187] 6. Kinetic Data Processing First, the results were smoothed over 10 points using the "smooth" option in KaleidaGraph software. After normalization with respect to the position of the cell on the rack, the start of each kinetic was adjusted to 0 before the addition of fibrillation buffer. Finally, the results of each kinetic were normalized to the fluorescence intensity of the 1p control 100 min after the start of polymerization, which was considered as 100%.
[0188] B. Results 1. Determination of the Critical Assembly Concentration As is known in the art, a limiting assembly concentration must be determined for each batch of VQIVYK peptide. The CCa for the batch used in this study was experimentally determined to be 32 μM.
[0189] 2. Optimization of fluorescence spectroscopy experiments In the case of thioflavin-T (ThT), an intercalator that allows the study of peptide polymerization, the wavelength values at which maximum fluorescence intensity for excitation and emission are observed have been observed to be 450 nm and 480 nm, respectively. These values were therefore used in the remaining experiments. The working concentration of ThT was set to 32 μM, a concentration at which ThT does not affect the polymerization rate. The concentration of 1p was set to 155 μM, at which satisfactory kinetics were obtained (data not shown).
[0190] 3. Effects of the 10 selected peptides on the polymerization of PHF6 As a first approach, we chose to work with a peptide concentration two times higher than 1p, i.e. 310 mM peptide concentration. Each of the 10 selected peptides was tested only at 1p (Figure 4).
[0191] The kinetics of 1p (red) starts with a nucleation step followed by a rapid polymerization (elongation) step, which tends towards a saturation step that forms a plateau. The kinetics of 1p+4p (blue) is similar to that of 1p alone, but the polymerization rate is slower (50% of 1p alone). The saturation plateau is reached with a fluorescence intensity equal to 80% of that of 1p alone. Thus, 4p inhibits the polymerization of 1p. In the presence of 23p (green), a longer nucleation step is observed, which means that it is slower to reach the maximum rate compared to 1p alone. Although the rate is slower (65% of that of 1p alone), the fluorescence intensity at 100 min is higher (161.7% of that of 1p alone), and it is likely to reach a higher plateau later. 23p is classified as a non-inhibitory peptide, since it is likely to associate with 1p to form amyloid structures. In the presence of 1tp (orange), it is difficult to distinguish the nucleation step. At the polymerization step, the rate is strongly inhibited (12% of the rate of 1p alone). Similarly, the fluorescence intensity at 100 min is very low (23.5% of that of 1p). Thus, 1tp is an inhibitory peptide.
[0192] As an example, the kinetics of the three peptides 1tp, 4tp, and 6tp in the presence or absence of 1p are shown in Figure 5. Although not shown, 4p and 5p are also of therapeutic interest.
[0193] Three peptides (1tp, 4tp, and 6tp) do not polymerize by themselves, as evidenced by near-zero fluorescence. 1p in the presence of 1tp or 6tp was found to exhibit a maximum polymerization rate and final fluorescence intensity that was clearly inhibited. Polymerization of these three peptides was followed for 15 hours (not shown). Over longer periods, the inhibitory effect was found to persist without significant changes.
[0194] After processing and analyzing all the kinetics in the presence of the different peptides, the fluorescence intensity and maximum polymerization rate of all selected peptides were compared (Figure 6). The effect of the different peptides was quantified and the peptides were classified. The inhibition threshold was set at 50% for the polymerization rate and 100% for the fluorescence intensity.
[0195] Based on these criteria, of the ten selected peptides tested, five peptides: 4p, 5p, 1tp, 4tp, and 6tp, exhibit significant inhibitory effects. The polymerization kinetics of 1p in the presence of selected peptides can be classified into three categories: kinetics showing very high speed and fluorescence intensity observed with 8p and 23p peptides; polymerization kinetics that largely follow the kinetics of 1p alone, e.g., observed with peptides 4p, 5p, 9p, 13p, and 14p; and kinetics that are slower and have lower fluorescence intensity compared to 1p alone, e.g., observed with 1tp, 4tp, and 6tp peptides.
[0196] The peptides that were found to show the most interesting inhibitory properties were tested several times to study their variants (Figure 7).
[0197] The inhibitory activity of selected hexapeptides was also studied in silico by molecular modeling using the raptorX program. Figure 8(A) shows a specific example of the effect of the 1tp hexapeptide on the PHF6-HKLTF interaction. Using the RaptorX software, it was further demonstrated that in the case of Alzheimer's disease, the PHF6 peptide (SEQ ID NO: 2) interacts with itself and with HKLTF in paired helical fibrils (PHFs). 374 HKLTF 378 (SEQ ID NO: 3) in silico (Figure 8B-I). It was also possible to test the in silico effect of some of the inhibitory peptides (6tp and 4tp) on this structure with different stoichiometries compared to the number of PHF6 / HKLTF pairs: 0.25 (Figure 8(B-II)), 0.50 (Figure 8(B-III)), 0.75 (Figure 8(B-IV)) and 1.00 (Figure 8B-V). Figure 9 shows the in silico prediction of the interaction of 4tp with free tau protein (R3 / R4 repeats) and with the PHF structure. This figure shows that 4tp first interacts with free tau protein, i.e. with its segment β1 (PHF6, 306 VQIVYK 311 ) strand, β4( 336 QEVVKS 342 - SEQ ID NO: 52) strand, β7 ( 356 SLDNITHV 363 - SEQ ID NO: 53) strand, and β8 ( 371 IETHKLTF 37 - SEQ ID NO: 54) strand and then interacts with the ends of PHFs. These results show that the 4tp peptide can inhibit the self-association process of free tau protein and also block the growth of PHFs.
[0198] C. Discussion The ten selected peptides were classified into three categories: peptides that "do not show any inhibitory effect", 8p, 9p, 13p, 14p, and 23p peptides; peptides that "show weak inhibitory effect", 4p, 5p, and 4tp peptides; and peptides that "show strong inhibitory effect", 1tp and 6tp peptides. Of the five selected peptides that are most interesting in terms of inhibition of PHF6 aggregation (4p, 5p, 1tp, 4tp, and 6tp), three (1tp, 4tp, 6tp) have a sequence with three amino acids at the same positions as 1p.
[0199] Future experiments include the study of 10 hexapeptides with the reverse sequence of the 10 selected hexapeptides. In addition, it will be interesting to test peptides 3p and 6p, which are very poorly amyloidogenic, despite being more aggregative than the 10 selected hexapeptides. Similarly, the effect of a mixture of hexapeptides on the aggregation of the PHF6 peptide will need to be tested. A VQIVYK / HKLTF interaction model will be developed and characterized, corresponding to the true interacting peptides within the human pathological tau protein β1 in the case of VQIVYK and β8 in the case of HKLTF, and the hexapeptides will be tested in this model. In vitro tests will be performed using a cell model expressing pathological human tau protein, followed by experiments in models expressing pathological human tau, in particular the zebrafish model developed at the ISERT (Institut de Recherche en Santé, Environnement et Travail) in Rennes (France). At the same time, the most efficient chemical modifications of the hexapeptides will be performed to make them useful in diagnostic methods and to improve their stability and other properties desirable for therapeutic use in humans.
[0200] Example 2 Evaluation of therapeutic and amyloidogenic hexapeptides in vivo. The effect of three hexapeptides classified as "therapeutic" (1tp, 4tp, 6tp) and two peptides classified as "amyloidogenic" (7tp and 1p) on the proliferation of cells of the neuroblastoma line SH-SY5Y was studied after 24 hours of treatment in the presence of the hexapeptides at a concentration of 100 μM in 1×DMEM medium, 8% serum. The results obtained are shown in FIG. 10(A). The images obtained clearly showed that the cells cultured in the presence of peptides classified as "therapeutic" appeared to be identical in appearance as well as in number to the control cells cultured in the absence of peptides. Conversely, when cells were cultured in the presence of peptides classified as "amyloidogenic", the number of cells appeared to be significantly reduced and they also looked different. Thus, compared to peptides classified as "amyloidogenic", peptides classified as "therapeutic" do not appear to show any effect on neuroblastoma cell proliferation.
[0201] The viability of these cells was evaluated by two different methods: using the MTT test after 24 and 48 hours of treatment with the various hexapeptides tested, and by counting the cells after 24 and 72 hours of treatment with the various hexapeptides. The results obtained are shown in FIG. 10(B). The results obtained using the two methods confirmed the observations made above. Cell proliferation was not affected in the presence of peptides classified as "therapeutic", in contrast to what was observed in the presence of peptides classified as "amyloidogenic". Moreover, cell proliferation was better in the presence of peptides classified as "therapeutic" compared to the control group. This can be explained by the presence in the peptide sequence of essential amino acids (V, I, and K) or semi-essential amino acids (Y) that promote cell proliferation.
[0202] In conclusion, this experiment demonstrated without any doubt that peptides classified and selected as "therapeutic" showed a general safety profile with regard to the proliferation of cells of the neuroblastoma line SH-SY5Y.
Claims
1. 1. An inhibitory peptide for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject, said inhibitory peptide consisting of or comprising a hexapeptide or a derivative thereof; - the hexapeptide is SEQ ID NO:5 (3p), SEQ ID NO:6 (4p), SEQ ID NO:18 (4p inv ), SEQ ID NO: 7 (5p), SEQ ID NO: 19 (5p inv ), SEQ ID NO:8 (6p), SEQ ID NO:9 (8p), SEQ ID NO:21 (8p inv ), SEQ ID NO: 10 (9p), SEQ ID NO: 22 (9p inv ), SEQ ID NO: 11 (13p), SEQ ID NO: 23 (13p inv ), SEQ ID NO: 12 (14p), SEQ ID NO: 24 (14p inv ), SEQ ID NO: 13 (23p), SEQ ID NO: 25 (23p inv ), SEQ ID NO: 14 (1tp), SEQ ID NO: 26 (1tp inv ), SEQ ID NO: 15 (4tp), SEQ ID NO: 27 (4tp inv ), SEQ ID NO: 16 (6tp), SEQ ID NO: 28 (6tp inv ), SEQ ID NO:55(0tp inv ), and SEQ ID NO: 56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - said hexapeptide derivative consists of an amino acid sequence selected from said group, said amino acid sequence comprising a single conservative amino acid substitution or said amino acid sequence comprising conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6, Inhibitory peptides.
2. the inhibitory peptide consists of or comprises a hexapeptide or a derivative thereof; - said hexapeptides are SEQ ID NO:5 (3p), SEQ ID NO:6 (4p), SEQ ID NO:7 (5p), SEQ ID NO:8 (6p), SEQ ID NO:9 (8p), SEQ ID NO:10 (9p), SEQ ID NO:11 (13p), SEQ ID NO:12 (14p), SEQ ID NO:13 (23p), SEQ ID NO:14 (1tp), SEQ ID NO:15 (4tp), SEQ ID NO:16 (6tp), SEQ ID NO:26 (1tp inv ), SEQ ID NO:55(0tp inv ), and SEQ ID NO: 56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - said hexapeptide derivative consists of an amino acid sequence selected from said group, said amino acid sequence comprising a single conservative amino acid substitution or said amino acid sequence comprising conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6, An inhibitory peptide for use according to claim 1.
3. the inhibitory peptide consists of or comprises a hexapeptide or a derivative thereof; - said hexapeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:6 (4p), SEQ ID NO:7 (5p), SEQ ID NO:9 (8p), SEQ ID NO:10 (9p), SEQ ID NO:11 (13p), SEQ ID NO:12 (14p), SEQ ID NO:13 (23p), SEQ ID NO:14 (1tp), SEQ ID NO:15 (4tp) and SEQ ID NO:16 (6tp); - said hexapeptide derivative consists of an amino acid sequence selected from said group, said amino acid sequence comprising a single conservative amino acid substitution or said amino acid sequence comprising conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6, An inhibitory peptide for use according to claim 1.
4. the inhibitory peptide consists of or comprises a hexapeptide or a derivative thereof; - the hexapeptide is SEQ ID NO:5 (3p), SEQ ID NO:6 (4p), SEQ ID NO:18 (4p inv ), SEQ ID NO: 7 (5p), SEQ ID NO: 19 (5p inv ), SEQ ID NO:8 (6p), SEQ ID NO:9 (8p), SEQ ID NO:21 (8p inv ), SEQ ID NO: 10 (9p), SEQ ID NO: 11 (13p), SEQ ID NO: 12 (14p), SEQ ID NO: 24 (14p inv ), SEQ ID NO: 25 (23p inv ), SEQ ID NO: 14 (1tp), SEQ ID NO: 26 (1tp inv ), SEQ ID NO: 15 (4tp), SEQ ID NO: 27 (4tp inv ), SEQ ID NO: 28 (6tp inv ), SEQ ID NO:55(0tp inv ), and SEQ ID NO: 56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - said hexapeptide derivative consists of an amino acid sequence selected from said group, said amino acid sequence comprising a single conservative amino acid substitution or said amino acid sequence comprising conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6, An inhibitory peptide for use according to claim 1.
5. the inhibitory peptide consists of or comprises a hexapeptide or a derivative thereof; - the hexapeptide is SEQ ID NO: 6 (4p), SEQ ID NO: 18 (4p inv ), SEQ ID NO: 7 (5p), SEQ ID NO: 19 (5p inv ), SEQ ID NO: 14 (1tp), SEQ ID NO: 26 (1tp inv ), SEQ ID NO: 15 (4tp), SEQ ID NO: 27 (4tp inv ), SEQ ID NO: 16 (6tp), SEQ ID NO: 28 (6tp inv ), SEQ ID NO:55(0tp inv ), and SEQ ID NO: 56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - said hexapeptide derivative consists of an amino acid sequence selected from said group, said amino acid sequence comprising a single conservative amino acid substitution or said amino acid sequence comprising conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6, An inhibitory peptide for use according to claim 1.
6. the inhibitory peptide consists of or comprises a hexapeptide or a derivative thereof; - said hexapeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:6 (4p), SEQ ID NO:7 (5p), SEQ ID NO:14 (1tp), SEQ ID NO:15 (4tp) and SEQ ID NO:16 (6tp), - said hexapeptide derivative consists of an amino acid sequence selected from said group, said amino acid sequence comprising a single conservative amino acid substitution or said amino acid sequence comprising conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6, An inhibitory peptide for use according to claim 5.
7. the inhibitory peptide consists of or comprises a hexapeptide or a derivative thereof; - the hexapeptides are SEQ ID NO: 14 (1tp), SEQ ID NO: 15 (4tp), SEQ ID NO: 16 (6tp), SEQ ID NO: 26 (1tp inv ), SEQ ID NO:55(0tp inv ), and SEQ ID NO: 56 (3tp inv (a) a sequence of amino acids selected from the group consisting of: - said hexapeptide derivative consists of an amino acid sequence selected from said group, said amino acid sequence comprising a single conservative amino acid substitution or said amino acid sequence comprising conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6, An inhibitory peptide for use according to claim 5.
8. the inhibitory peptide consists of or comprises a hexapeptide or a derivative thereof; - said hexapeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 14 (1tp) and SEQ ID NO: 16 (6tp), - said hexapeptide derivative consists of an amino acid sequence selected from said group, said amino acid sequence comprising a single conservative amino acid substitution or said amino acid sequence comprising conservative amino acid substitutions at two of positions 1, 3 and 5 or at two of positions 2, 4 and 6, An inhibitory peptide for use according to claim 5.
9. 9. The inhibitory peptide for use according to any one of claims 1 to 8, wherein the hexapeptide or hexapeptide derivative is linked to a heterologous moiety selected from the group consisting of a detectable moiety, a cell penetrating agent, a stability enhancing moiety, a tag enabling cellular degradation, and a blood-brain barrier shuttle moiety.
10. 10. The inhibitory peptide for use according to claim 9, wherein the hexapeptide or hexapeptide derivative is linked to a detectable moiety and to a heterologous moiety selected from the group consisting of a cell penetrating agent, a tag enabling cellular degradation, a stability enhancing moiety, and a blood-brain barrier shuttle moiety.
11. The hexapeptide or the hexapeptide derivative may be linked to a detectable moiety suitable for detection by positron emission tomography (PET), in particular 11 C. 13 N, 15 O. 18 F, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 44 Sc, 43 Sc, 47 Sc, 124 I, 76 Br, and 82 11. The inhibitory peptide for use according to claim 9 or claim 10, which is linked to a radionuclide selected from the group consisting of Rb.
12. 11. The inhibitory peptide for use according to claim 9 or claim 10, wherein the hexapeptide or the hexapeptide derivative is linked to a detectable moiety, the detectable moiety being a multimodal nanoparticle.
13. The inhibitory peptide for use according to any one of claims 1 to 12, wherein the hexapeptide or hexapeptide derivative is cyclized.
14. A combination of at least two inhibitory peptides according to any one of claims 1 to 13 for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject.
15. A pharmaceutical composition comprising at least one inhibitory peptide according to any one of claims 1 to 13 and at least one pharma- ceutically acceptable carrier or excipient for use in the diagnosis and / or treatment of a tauopathy or a disorder associated with abnormal tau aggregation in a subject.
16. 16. The pharmaceutical composition for use according to claim 15, further comprising at least one additional biologically active agent.
17. The inhibitory peptide according to any one of claims 1 to 13, or the combination according to claim 14, or the pharmaceutical composition according to claim 15 or 16, wherein the diagnosis is the diagnosis of an early stage of a tauopathy.
18. The inhibitory peptide of any one of claims 1 to 13, or the combination of claim 14, or the pharmaceutical composition of claim 15 or 16, wherein the diagnosis is used to monitor the effectiveness of a tauopathy treatment in a patient.
19. The tauopathy includes Alzheimer's disease (AD), Pick's disease (PD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), age-related tau astrogliopathy (ARTAG), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), subacute sclerosing panencephalitis (SSPE), Guadeloupe-type parkinsonism, Western Pacific amyotrophic lateral sclerosis and parkinsonism-dementia complex (ALS / PDC), chronic 19. An inhibitory peptide for use according to any one of claims 1 to 13 and 17 to 18, or a combination for use according to any one of claims 14 and 17 to 18, or a pharmaceutical composition for use according to claims 15 to 18, selected from the group consisting of chronic traumatic encephalopathy (CTE), Huntington's disease (HD), Niemann-Pick disease type C (NPC), Down's syndrome, post-encephalitic parkinsonism (PEP), and myotonic dystrophy (types 1 and 2), in particular Alzheimer's disease (AD) and Pick's disease (PD).
Citation Information
Patent Citations
Structure-based peptide inhibitors of alpha-synuclein aggregation
WO2018005867A2
